An aged circulatory environment can activate microglia, reduce neural precursor cell activity and impair cognition in mice. We hypothesized that brain endothelial cells (BECs) mediate at least some of these effects. We observe that BECs in the aged mouse hippocampus express an inflammatory transcriptional profile with focal upregulation of vascular cell adhesion molecule 1 (VCAM1), a protein that facilitates vascular-immune cell interactions. Concomitantly, levels of the shed, soluble form of VCAM1 are prominently increased in the plasma of aged humans and mice, and their plasma is sufficient to increase VCAM1 expression in cultured BECs and the hippocampi of young mice. Systemic administration of anti-VCAM1 antibody or genetic ablation of Vcam1 in BECs counteracts the detrimental effects of plasma from aged individuals on young brains and reverses aging aspects, including microglial reactivity and cognitive deficits, in the brains of aged mice. Together, these findings establish brain endothelial VCAM1 at the blood-brain barrier as a possible target to treat age-related neurodegeneration.
B
rain structure and function deteriorate with age, steadily driving cognitive impairments and susceptibility to neurodegenerative disorders in humans 1 . How aging leads to these manifestations is poorly understood, but an increase in the activation of microglia, frequently referred to as 'neuroinflammation' (refs. [2] [3] [4] ), and a precipitous loss of stem cell numbers and activity in the dentate gyrus (DG) of the hippocampus, one of two neurogenic regions of the adult mammalian brain 5 , are commonly noted. The hippocampus is crucial for learning and memory and is particularly vulnerable to age-related neurodegeneration and diseases such as Alzheimer's disease (AD) 6 . Although many of these age-related changes in the brain may be the consequences of cell-intrinsic and brain-localized mechanisms of aging, we asked whether changes in secreted signaling proteins, dubbed the communicome 7 , could be used to understand, characterize and quantify aspects of brain aging and cognitive impairment. Indeed, not only are such changes in plasma or cerebrospinal fluid proteomes abundant with aging and disease 8, 9 , but factors in blood or plasma from young mice or humans are also sufficient to increase brain function in the hippocampus 8, 10, 11 and the subventricular zone (SVZ) 12 . Conversely, young mice exposed to blood from aged individuals showed reduced neurogenesis and cognitive function in the hippocampus 8, 13 . Considering the tight regulation of transport of molecules across the blood-brain barrier (BBB) and its role as a protective barrier with limited permeability to macromolecules 14 , it is currently unclear how factors promoting youth or aging may modulate brain function 1 . Here we investigated the interaction between the circulating communicome and BECs in the context of brain aging.
Results
Aged BECs are transcriptionally activated. To determine the transcriptional changes associated with aging in BECs, we acutely isolated and pooled primary CD31 + BECs from the cortices and hippocampi of young (3-month-old) and aged (19-month-old) mice and analyzed their transcriptome using RNA-seq (Extended Data Fig. 1a,b) . Unsupervised clustering analysis revealed prominent age-dependent differences in the transcriptome, with over 1,000 differentially expressed genes (Fig. 1a) . Cell purity was confirmed on the basis of high gene expression values for genes with BEC-specific expression and very low or undetectable expression for other celltype-specific markers of the central nervous system (CNS) (Fig. 1b and Extended Data Fig. 1c) . GeneAnalytics pathway analysis of differentially expressed genes identified numerous pathways associated with aging (Supplementary Table 1) , including cell adhesion, immune cell activation, stress response and vascular remodeling 15 . Analysis of the highly expressed and differentially expressed transcripts revealed an inflammatory and activated profile with age,
Aged blood impairs hippocampal neural precursor activity and activates microglia via brain endothelial cell VCAM1
Articles NATurE MEDiCiNE as illustrated by the increase in mRNA levels for the major histocompatibility complex (MHC) class I molecules B2m (β2-microglobulin) and H2-K1, two of the most highly expressed transcripts in BECs (Fig. 1c) . Tspo, a marker of neuroinflammation commonly used in human positron emission tomography (PET) scans to assess the level of microglial activation in neurodegenerative diseases 16 , was highly expressed in BECs and also had significantly increased expression with age, as was the case for Vwf (von Willebrand factor), which encodes a blood glycoprotein involved in hemostasis that has elevated levels under acute and chronic inflammation and is known to promote vascular inflammation 17 ( Fig. 1c) .
VCAM1 levels increase with age and exposure to systemic inflammatory mediators. To identify proteins whose abundance changes with age in humans and are possibly associated with the BBB and cerebrovascular dysfunction, we searched for proteins involved in vascular function in the healthy aging control group in a previously published plasma proteomics dataset from our laboratory 9 . Concentrations of 31 factors correlated significantly with age ( Fig. 1d and Supplementary Table 2 ; P < 0.05). Of these, eight were expressed in mouse BECs at the transcript level (Supplementary  Table 2 and Extended Data Fig. 1d ,f) and five have vascular-, endothelial-or angiogenesis-related functions (Supplementary Table 2 ; GeneCards). Among the proteins expressed in or related to the vasculature, soluble VCAM1 (sVCAM1) correlated most strongly with age ( Fig. 1e ) and its levels were increased in an independent cohort of healthy individuals (Fig. 1f) . VCAM1, a member of the immunoglobulin superfamily, is upregulated on endothelium in response to inflammation throughout the body, where it facilitates leukocyte tethering through the integrin receptor α 4 β 1 (also known as VLA-4) and transmigration into tissues 18, 19 . VCAM1 is shed constitutively through proteolytic cleavage by the membrane-bound metalloproteinase ADAM17, resulting in high quantities of plasma sVCAM1 (ref. 20 ). Similarly to humans, mice showed a significant increase in plasma sVCAM1 abundance with more advanced age (19 months) that was not seen in middle age (10) (11) (12) Fig. 1g ).
This increase in sVCAM1 levels in plasma was associated with a significant increase in VCAM1 expression in cells immunoreactive for lectin and MECA-99, markers of cerebral blood vessels, in the DG of aged mice ( Fig. 1h ,i) 21, 22 . This increase was confirmed by quantifying CD31 +
VCAM1
+ BECs in the cortices and hippocampi of young and aged mice (Extended Data Fig. 1g-i) . Interestingly, exposure to blood from aged mice through heterochronic parabiosis induced a similar increase in VCAM1 immunoreactivity in young mice (Fig. 1j and Extended Data Fig. 1k ) and a concomitant increase in sVCAM1 levels in plasma (Extended Data Fig. 1j ). In a bulk population of BECs, mRNA levels of molecules involved in leukocyte adhesion were low or undetectable (Extended Data Fig. 1d) . At the protein level, VCAM1 expression was visible in a small percentage of BECs (Extended Data Fig. 1g-i) , suggesting that different populations and regions of BECs at the BBB respond uniquely to an aged systemic milieu.
Considering the heterogeneity of the BBB (Fig. 2a) and the low percentage of BECs that express VCAM1 d , and Extended Data Fig. 1g-i) , we performed single-cell RNAseq (scRNA-seq) on VCAM1 + -enriched BECs to characterize the unique molecular and phenotypic nature of rare VCAM1 + BECs. Full-length scRNA-seq was performed on 160 and 112 BECs isolated from pooled hippocampi from young and aged mice, respectively. We infused a fluorescently labeled anti-VCAM1 monoclonal antibody retro-orbitally before mouse perfusion and tissue dissection, which allowed us to enrich VCAM1 + BECs by up to 50% via cell sorting (Methods and Extended Data Fig. 1g-i ). All isolated cells expressed both pan-endothelial (Pecam1, Cldn5) and BBB-specific (Slco1c1, Slc2a1, Abcb1a, Ocln) markers (Extended Data Fig. 1l ; refs. [23] [24] [25] [26] ). Furthermore, we verified that VCAM1 protein levels correlated with Vcam1 mRNA levels (Extended Data Fig. 1m ,n). Unsupervised clustering in principal-component space using the top 2,500 correlated and anticorrelated genes identified three molecularly distinct populations (Fig. 2b) . The isolated VCAM1
+ cells were confined to two subpopulations (Fig. 2c and Supplementary  Table 3 ). Interestingly, none of the clusters was significantly enriched for cells from young or aged mice, indicating that strong sources of variation exist besides age that result in transcriptional heterogeneity between the BEC subpopulations (Extended Data Fig. 1o ). In spite of this, a direct comparison of Vcam1 expression levels within isolated CD31 +
high BECs showed significantly higher Vcam1 mRNA levels in BECs from aged as compared to young mice (Extended Data Fig. 1p ). Transcripts for other adhesion molecules, namely Sele (E-selectin) and Selp (P-selectin), were undetectable in the isolated BECs with scRNA-seq, in agreement with the absence of their detection in bulk RNA-seq (Extended Data Fig. 1d ). Icam1 transcript, primarily enriched in the venous Vcam1 + cluster (Fig. 2h ), was coexpressed in few VCAM1 + BECs from young or aged mice as well as all BECs analyzed and did not show increased expression with age (Extended Data Fig. 1q ). age, and systemic and cerebrovascular VCAM1 levels increase with age and heterochronic parabiosis. a, Heat map displaying up-and downregulated genes in young versus aged BECs based on bulk RNA-seq (n = 6 young and 6 aged biologically independent samples; each sample corresponds to biologically independent cortices or hippocampi pooled from two mice). There were 1,006 genes with significant differential expression (*q < 0.05, Cuffdiff statistical package 61 ). b, Fragments per kilobase of transcript per million mapped reads (FPKM) of cell-type-specific markers for BECs. n = 6 young and 6 aged biologically independent samples. Data are shown as the mean ± s.e.m. c, FPKM values of inflammation-and activationrelated genes. n = 6 young and 6 aged biologically independent samples. Data are shown as the mean ± s.e.m. Specific q values shown were derived from the Cuffdiff statistical package. See the Methods for details; source data are available online. d, Heat map showing changes in gene expression for 31 of 74 human plasma factors with aging (P < 0.05, Spearman's correlation coefficient). A multiplex assay was used (n = 118 healthy humans). e, Spearman correlation of sVCAM1 protein levels and age (Spearman's correlation coefficient = 0. 47, P = 7.7 × 10 -8 , q = 5.72 × 10 −6 ). f, Human sVCAM1 concentration in plasma from 11 young (<25 years old) and 11 aged (>65 years old) individual healthy donors, as determined by ELISA. **P = 0.0033, Student's t test, two tailed. Data are shown as the mean ± s.e.m. g, Mouse sVCAM1 concentration in plasma from young (3-month-old; n = 8) , middle-aged (8-to 10-monthold; n = 10) and aged (19-month-old; n = 8) mice as determined by ELISA. Data are shown as the mean ± s.e.m. ***P = 0.0001, ****P < 0.0001, one-way analysis of variance (ANOVA) with Tukey's multiple-comparisons test. mo, months. h, Representative confocal images in the DG of young (3-monthold) or aged (18-month-old) mice given retro-orbital (r.o.) injections of fluorescently conjugated anti-VCAM1 and anti-MECA-99 antibodies 2 h before perfusion. Hoechst labels cell nuclei. Arrowheads indicate VCAM1 + vessels. Three-dimensional renderings (3D) of the two-dimensional images (2D) are displayed. Scale bars, 50 µm. i, Quantification of VCAM1 + lectin + brain vasculature in hippocampi from young, middle-aged and aged mice. n = 12 young (3-to 4-month-old), 5 middle-aged (12-month-old) , 11 aged (18-month-old) and 6 very aged (24-month-old) mice. VCAM1 was quantified in four separate cohorts of mice spaced 6 months or more apart. Data are shown as the mean ± s.e.m. ***P = 0.0002, ****P < 0.0001, one-way ANOVA with Tukey's multiple-comparisons test. j, Quantification in the DG of VCAM1 + lectin + brain vasculature of young isochronic or heterochronic parabionts 5 weeks after surgery. Representative images are shown in Extended Data Fig. 1k . **P = 0.0071, Student's t test, two tailed. Data are shown as the mean ± s.e.m. n = 8 mice in the young isochronic (Iso) group and 13 mice in the young heterochronic (Het) group from two independent experiments.
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Among the three unique clusters, we identified one population largely negative for Vcam1 mRNA characterized by expression of genes relating to BBB metabolism, transport and the capillary phenotype ( Fig. 2c-f) . Interestingly, the remaining two clusters were both positive for Vcam1 expression but were molecularly distinct, with one expressing slightly higher levels of Vcam1 (C1) than the other (C2) (Fig. 2c) . By using a biased classification method with known markers of the three main vessel types found in the BBB (Extended Data Fig. 2a ; refs. [23] [24] [25] [26] ), we found the Vcam1 + C2 cluster to express significantly higher levels of proinflammatory genes (Vwf among others) and postcapillary venous (venule and vein) markers (Nr2f2, Ephb4), whereas the Vcam1 + C1 cluster expressed genes involved in vascular remodeling and Notch signaling (Vegfc, Notch1 and Edn1, among others) and arterial (artery and arteriole) classification markers (Bmx, Efnb2, Jag1) (Fig. 2d and Extended Data Fig. 2a, b; GeneCards; ). We further applied the Mann-Whitney test to find differentially expressed genes between the three BEC subpopulations in an unbiased manner (Fig. 2e) . Indeed, the Vcam1 + venous cluster was enriched for inflammatory and cytokine signaling genes 
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NATurE MEDiCiNE (Tspo, Lrg1, Hif1a and B2m, among others) and pathways including tumor necrosis factor (TNF)-α, NF-κB and cytokine signaling, among others ( Fig. 2e-i ; GeneCards). The Vcam1 + arterial cluster was differentially characterized by genes involved in matrix remodeling, migration and proliferation (Fbln5, Mgp, Bgn) and pathways including innate immunity, integrin and vasoendothelial growth factor (VEGF) signaling (Fig. 2e-g ), Notch signaling genes and factors related to neurogenesis (Extended Data Fig. 2a,b ; GeneCards; refs. [23] [24] [25] [26] [27] [28] ). Venous and arterial Vcam1 + BECs expressed Tnfrsf1a, Il1r1, Il6ra and Il6st (Fig. 2i) , which encode receptors for the inflammatory cytokines TNF-α, IL-1β and IL-6, respectively, known to induce VCAM1 through NF-κB signaling 29, 30 and increased in the circulation in neurodegeneration and aging 31, 32 . Indeed, recombinant TNF-α and IL-1β, but not IL-6, were sufficient to induce VCAM1 expression in the hippocampus following retro-orbital injection in mice ( Fig. 2j ) or in cultured BECs (Extended Data Fig. 2c-e) .
Plasma from aged mice increases VCAM1 expression, reduces NPC activity and increases microglial reactivity. To determine whether soluble factors in blood can increase cerebrovascular VCAM1 levels, we added plasma from aged mice to cultured BECs or infused it into young mice. Plasma from aged mice added to acutely isolated primary mouse BECs or a tranformed mouse brain endothelial cell line, Bend.3 cells, significantly increased VCAM1 protein amount in comparison to plasma from young mice, whereas other adhesion molecules, namely ICAM1, E-selectin and P-selectin, were not significantly upregulated at the protein (Extended Data Fig. 2f -i) or mRNA (Extended Data Fig. 1d ,q) level. Likewise, plasma from aged but not young mice infused into young mice (retro-orbitally) caused a significant increase in VCAM1 expression in lectin-positive blood vessels and acutely isolated BECs (Fig. 3a-d) , whereas ICAM1 levels were not changed (Extended Data Fig. 2j,k) .
In line with previous findings 8, 13 , infusions with plasma from aged mice reduced the numbers of BrdU + proliferating cells overall, as well as the numbers of BrdU + SOX2 + neural progenitor cells (NPCs; Fig. 3e ,f) and doublecortin (DCX) + immature neurons (Fig. 3g,h ), in the granule cell layer (GCL) of the DG of young mice.
Administration of recombinant TNF-α or lipopolysaccharide (LPS) in young mice also reduced NPC proliferation (Extended Data Fig. 2l,m) . There was no change in the number of quiescent BrdU
+ neural stem cells in the SGZ in mice treated with plasma from aged mice (Fig. 3f ). Acute injections with plasma from aged mice also induced a prominent response in microglia, manifested as increased IBA1 immunoreactivity overall, expression of CD68 in IBA1 + cells and increased numbers of CD68 + IBA1 + microglia (Fig. 3i,j) . The total number of microglia did not change with this short-term plasma treatment (Fig. 3j) . Similarly to plasma from aged mice, repeated injections with plasma from aged humans over 3 weeks induced a prominent increase in BEC-specific VCAM1 expression in young immunodeficient NOD-scid IL-2Rγ null (NSG) mice (Extended Data Fig. 3a,b) , reduced NPC activity and increased microglial reactivity (Extended Data Fig. 3c,d + -enriched BECs from young and aged mice. a, Schematic of the BBB. Nutrient-rich, oxygenated blood is pumped into the brain through cerebral arterial BECs (arteries and arterioles), which are protected and supported by smooth muscle cells (SMCs) that cover the endothelium and form a basement membrane layered by astrocytic end-feet of the brain parenchyma. The blood is transferred to highly specialized capillaries, which comprise BECs that form unique tight junctions and are wrapped by pericytes (Peric.) within the endothelial basement membrane; these are in turn covered by astrocytic end-feet. BBB capillaries are the site of controlled transport of fluids and solutes into the CNS. Immune surveillance and occasional extravasation of leukocytes (Leuk.) into the CNS parenchyma occur at the level of postcapillary venous cells (venules and veins), the vascular segments into which blood flows after passing through the capillaries. Postcapillary venules have enlarged perivascular space between the endothelial and astrocytic basement membranes where immune cells can occasionally reside 62, 63 . b, Unbiased clustering of 112 aged and 160 young hippocampal BECs using whole-transcriptome data and visualization with tSNE reveals three molecularly distinct BEC populations. c, Violin plots of Vcam1 show differing levels of the transcript in each of the cell clusters. Minima, maxima, medians and percentiles are listed in Supplementary Table 4 ; n = 146 capillary BECs, n = 59 venous BECs and n = 67 arterial BECs pooled from eight mouse hippocampi. c.p.m., counts per million. d, Dot plot comparing the expression (scaled transcript counts and percent of population expressing) of various classical inflammatory, Notch signaling, arteriolar, venular and capillary markers between the three clusters (cluster 0, Vcam1 negative; cluster 1, Vcam1 positive; cluster 2, Vcam1 positive). e, Heat map of scaled expression of the top ten most enriched genes (differentially expressed with P < 0.05, Mann-Whitney test, two sided) in each cluster. Genes are ranked by highest log-transformed fold change when compared to all other cells. f, tSNE visualization colored by Vcam1 expression level. Clusters are further annotated by their putative functional phenotype and vessel segmental identity; n = 146 capillary BECs, n = 59 venous BECs and n = 67 arterial BECs pooled from the hippocampi of eight mice. g, GeneAnalytics (GSEA package) BEC pathway analysis of the Vcam1 + venous and arterial hippocampal BEC clusters. The top ten pathways containing Vcam1 are highlighted here, along with the number of genes in each pathway enriched and the score assigned to each pathway. h, Violin plots of expression of various inflammation-related genes in each of the three distinct clusters. The age-related chemokine Ccl11 and its receptor, Ccr3, were not found to be expressed in isolated CD31 + BECs. Minima, maxima, medians and percentiles are listed in Supplementary Table 4 ; n = 146 capillary BECs, n = 59 venous BECs and n = 67 arterial BECs pooled from the hippocampi of eight mice. i, Violin plots of expression of cytokine receptors enriched in the Vcam1 + venous cluster. Minima, maxima, medians and percentiles are listed in Supplementary Table 4 ; n = 146 capillary BECs, n = 59 venous BECs and n = 67 arterial BECs pooled from the hippocampi of eight mice. j, Young (2.5-month-old) mice were injected with PBS control (n = 5 mice at high dose and 3 mice at low dose), TNF-α (n = 3 mice at high dose and 4 mice at low dose), IL-1β (n = 4 mice at high dose and 4 mice at low dose) or IL-6 (n = 4 mice at low dose) retro-orbitally (r.o.) daily over 5 d (2 µg per injection; low dose) or acutely (10 µg; high dose). Representative confocal images (bottom) and quantification (top) are shown for VCAM1 staining in the DG. Scale bar, 100 µm. Data are shown as the mean ± s.e.m. *P = 0.027, **P = 0.041, ***P = 0.028, ****P = 0.006, one-way ANOVA with Dunnett's multiple-comparisons test.
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Vcam1 deletion following tamoxifen injections while using a systemic LPS inflammation model (Extended Data Fig. 4d-g ). Systemic LPS administration significantly upregulated BEC-specific VCAM1 levels in tamoxifen-treated Slco1c1-Cre ERT2-/-; Vcam1 fl/fl (Cre -) control mice, but not in tamoxifen-treated Cre + littermates (Extended Data Fig. 4d-g ), and reduced VCAM1 protein amount in the blood vessels of Cre + mice (Extended Data Fig. 3j ,k).
We next investigated how short-term administration of plasma from aged mice affects young mice in the absence of brain endothelial-and epithelial-specific Vcam1 (Fig. 4a) . While VCAM1 expression was absent in Cre + brains, sVCAM1 levels remained high in the plasma of all tamoxifen-treated mice, indicating unperturbed peripheral expression (Fig. 4b-d) . Notably, Vcam1 deletion in Cre Fig. 4e-i) . Moreover, plasma from aged mice also failed to induce microglial reactivity, as indicated by the levels of CD68 in IBA1 + cells (Fig. 4j,k) . Similarly to wild-type mice ( Fig. 3) , Cre -control mice showed reduced NPC activity and increased microglial activation when exposed to plasma from aged mice ( Fig. 4e-k) . Likewise, long-term administration of plasma from aged mice did not induce microglial reactivity or inhibit NPC activity in the DG of young Cre + mice lacking VCAM1 (Extended Data Fig. 5a-j) . Interestingly, young mice lacking brain endothelial and epithelial Vcam1 for 3 weeks of young adulthood showed a lower baseline number of BrdU +
SOX2
+ NPCs in the hippocampus, whereas microglial number and activation were not affected (Extended Data Fig. 3e-i) . It is possible that VCAM1 has additional functions in the maintenance of adult NPCs in young mice, as reported for the SVZ 35 and discussed in more detail below. Notably, depletion of sVCAM1 from the plasma of aged humans before in vivo administration (Extended Data Fig. 6a-d ) did not significantly change its adverse effects on NPC activity and microglial reactivity in young mice (Extended Data Fig. 6e-j) , indicating that high levels of circulating sVCAM1 do not drive aging phenotypes in the young brain.
Monoclonal anti-VCAM1 antibody prevents detrimental effects of plasma from aged humans and mice . Leukocytes bind to VCAM1 primarily through α 4 β 1 integrin, also known as ), and an antibody against VLA-4 is used to treat multiple sclerosis and Crohn's disease 37 . Blockade of the VCAM1-VLA-4 interaction also reduced seizures in a mouse model 15 , prompting us to determine whether anti-VCAM1 antibody treatment would mimic the effects of genetic Vcam1 deletion and antagonize the effects of plasma from aged individuals (Fig. 5a ). Treatment with a well-characterized anti-VCAM1 antibody that binds to immunoglobulin domains 1 and 4 of the extracellular domain of the protein and prevents leukocyte tethering 38 did not affect the increase in VCAM1 expression in brain endothelium following infusion with plasma from aged humans (Fig. 5b,e) , whereas it completely prevented the inhibitory effects of plasma from aged humans on NPC activity (Fig. 5c ,f) and microglial reactivity (Fig. 5d,g ). In contrast, in PBS-treated control mice, anti-VCAM1 treatment had no effects on these parameters. Anti-VCAM1 antibody treatment similarly prevented the detrimental effects of plasma from aged humans in young NSG mice (Extended Data Fig. 6k-p) .
To determine whether plasma from aged mice reduced the survival of newborn cells in the DG of the hippocampus and whether anti-VCAM1 treatment antagonized this effect, we pulsed young mice with 5-ethynyl-2′-deoxyuridine (EdU) before treatment with plasma from aged mice and antibodies (Fig. 5h) . As shown earlier, young mice treated with plasma from aged mice and IgG isotype control antibody had reduced cell proliferation as assessed by numbers of BrdU + cells and BrdU + SOX2 + NPCs, and this was reversed with anti-VCAM1 treatment (Fig. 5i,j) (Fig. 5k-n) . These effects of plasma from aged mice were prevented by anti-VCAM1 treatment. Survival of immature Edu +
DCX
+ cells was not affected (Fig. 5l-n) .
To investigate whether these overall beneficial effects of VCAM1 inhibition and depletion were linked to overt changes in BBB integrity, we injected young and aged Vcam1-deficient mice and mice exposed to traumatic brain injury (TBI) with a nonfixable 70-kDa tracer and perfused them 3 h later with a fixable 2-MDa tracer. We observed no differences in dextran diffusion in the hippocampus as a result of BEC VCAM1 expression, with the caveat that non-fixable tracers may underestimate BBB permeability 39 (Extended Data Fig. 7a-d) . Additionally, we did not observe an age-related change in the mRNA levels of the major tight junction or BBB permeability genes Cldn5 (claudin-5), Ocln (occludin), Tjp1 (ZO-1) and Plvap (plasmalemma vesicle-associated protein) at the single-cell level, although in bulk populations of BECs Tjp1 or Pvlap levels were reduced with age ( Fig. 1b and Extended Data Fig. 1e,r) . Likewise, we observed no significant changes in the number of microglia, T cells, B cells, neutrophils, monocytes, macrophages or natural killer cells between young and aged mice with and without short-or long-term deletion of Vcam1 in BECs when using flow cytometry (Extended Data Figs. 7e, f and 8) . Expression of VLA-4 did not affect this result with the exception of VLA-4 + microglia, which had increased numbers in 22-month-old Cre + mice lacking Vcam1 in BECs (Extended Data Fig. 8c ); in addition, we observed an increase in the number of CD45 + CD11b + CD11c + IAIE + dendritic cells in the brains of aged mice regardless of VCAM1 expression (Extended Data Fig. 8j ).
To determine whether the VCAM1 ligand VLA-4 is similarly involved in regulating age-related NPC activity and microglial reactivity, we treated aged wild-type mice with anti-VLA-4 antibody, which did not affect VCAM1 levels in the hippocampus + vessels. Scale bar, 100 µm. ****P = 0.0001, two-tailed Student's t test. Data are shown as the mean ± s.e.m. n = 10 mice treated with young mouse plasma and 11 mice treated with aged mouse plasma. c, Top, histogram plots of CD31 + VCAM1 + cells isolated from LPSstimulated young (3-month-old) wild-type mice injected (r.o.) with fluorescently tagged (DL488) anti-VCAM1 monoclonal antibody or IgG isotype control 2 h before they were killed. This was done to set the gating for CD31 +
VCAM1
+ BECs. Bottom, flow gating and histogram plots of pooled (n = 4 mice per plasma treatment) hippocampi isolated from plasma-injected young mice. To label VCAM1 + BECs, mice were injected (r.o.) with fluorescently tagged anti-VCAM1 monoclonal antibody 2 h before they were killed. d, Quantification of CD31 +
+ cells isolated from healthy cortex (n = 4 mice per plasma treatment, individually measured) (left) and four technical replicates of hippocampi that were pooled from four mice per plasma treatment group (right). Data are shown as the mean ± s.e.m. *P = 0.017, two-tailed Student's t test. e,f, Representative confocal images (e) and quantification (f) in the DG and SGZ of BrdU + , SOX2
+ and GFAP + cells. Scale bar, 100 µm. Purple lines outline the SGZ and arrowheads indicate proliferating NPCs. **P = 0.009, *P = 0.028, two-tailed Student's t test. Data are shown as the mean ± s.e.m. n = 10 mice treated with young mouse plasma and 11 mice treated with aged mouse plasma. NSCs, neural stem cells. g,h, Representative confocal images (g) and quantification (h) in the GCL of DCX + cells (white). Scale bar, 100 µm. ***P = 0.0001, two-tailed Student's t test. Data are shown as the mean ± s.e.m. n = 10 mice treated with young mouse plasma and 11 mice treated with aged mouse plasma. i,j, Representative confocal images (i) and quantification (j) in the DG of CD68 + and IBA1 + cells. Scale bar, 100 µm. ***P = 0.0047, **P = 0.0011, *P = 0.031, two-tailed Student's t test. Data are shown as the mean ± s.e.m. n = 10 mice treated with young mouse plasma and 11 mice treated with aged mouse plasma.
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(Extended Data Fig. 9a,b,d ). While we observed a reduction in the numbers of IBA1 +
CD68
+ activated microglia, neural progenitor proliferation was unaffected (Extended Data Fig. 9c ,e,f).
To determine whether the increase in VCAM1 as a result of normal aging (Fig. 1 ) might mediate similar negative effects on the aged brain as plasma from aged humans and mice does on a young brain, we treated aged male wild-type mice with anti-VCAM1 antibody (Fig. 6a) . Strikingly, mice treated with anti-VCAM1 antibody for 3 weeks exhibited a general increase in the number of BrdU + cells as well as BrdU + SOX2 + NPCs (Fig. 6b,d ) and a significant reduction in the number of IBA1 +
+ activated microglia (Fig. 6c,e) . In agreement with these results, Cre + mice lacking Vcam1 long term from 2 to 18 months showed reduced microglial activation and increased NPC proliferation (Fig. 6f-h and Extended Data Fig. 9g,h ). Anti-VCAM1 antibody treatment similarly promoted NPC proliferation and reduced microglial activation in aged female mice, which, like male mice, showed age-related increases in the levels of soluble and BEC-specific VCAM1 (Extended Data Fig. 5k-o) . Table 3 ). b, Representative confocal images in the DG of staining for VCAM1, MECA-99 and AQP4. Hoechst labels cell nuclei. Scale bars, 200 µm (merged images, left) and 50 µm (magnified VCAM1 and MECA-99 merged images (outlined with white boxes), right). Tissue was stained and VCAM1 was measured in all 31 mice in this study. 
SOX2
+ quantification (g) in the DG of brain sections immunostained for BrdU and SOX2. White dashed lines outline the SGZ. Scale bars, 200 µm. *P = 0.02, **P = 0.017, two-way ANOVA with Tukey's multiple-comparisons test. Data are shown as the mean ± s.e.m. n = 7 Cre -mice and 8 Cre + mice administered young mouse plasma and 8 Cre -mice and 8 Cre + mice administered aged mouse plasma. h,i, DCX quantification (h) and representative confocal images (i) in the GCL. Hoechst labels cell nuclei. Scale bar, 100 µm. **P = 0.0015, two-way ANOVA with Tukey's multiple-comparisons test. Data are shown as the mean ± s.e.m. n = 7 Cre -mice and 8 Cre + mice administered young mouse plasma and 8 Cre -mice and 8 Cre + mice administered aged mouse plasma. j,k, Representative confocal images (j) and quantification (k) in the DG of CD68 and IBA1. Hoechst labels cell nuclei. Scale bars, 100 µm. ****P = 0.0008, ***P = 0.0061, two-way ANOVA with Tukey's multiple-comparisons test. Data are shown as the mean ± s.e.m. n = 7 Cre -mice and 8 Cre + mice administered young mouse plasma and 8 Cre -mice and 8 Cre + mice administered aged mouse plasma.
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To test whether anti-VCAM1 therapy exerts cognitive benefits, we treated young and aged NSG and C57BL/6 mice with anti-VCAM1 antibody or IgG as a control and tested them in contextual fear conditioning, novel object recognition and Barnes maze tasks, established paradigms to assess age-related impairments in hippocampal-dependent learning and memory 10, 11 . Remarkably, aged C57BL/6 mice treated with anti-VCAM1 antibody, but not with IgG, reached the escape hole in the Barnes maze with similar efficiency as young mice on the final two testing days, and they showed significantly increased interaction with a novel object in comparison to IgG-treated mice ( Fig. 6i,j) . Thirteenmonth-old NSG mice, which exhibit accelerated age-related cognitive decline 11 , showed increased interaction with a novel object (Extended Data Fig. 9i ) but no significant difference in contextual freezing (Extended Data Fig. 9j ,k) upon treatment with anti-VCAM1 antibody for 1 month. Likewise, a cohort of 23-month-old C57BL/6 wild-type mice, in which all mice exhibited similar baseline freezing (Extended Data Fig. 9l ), demonstrated a significant increase in contextual ( 
Discussion
Our studies uncovered a new role for the endothelial cell adhesion molecule VCAM1 in regulating brain function with aging. Maybe most surprisingly and of potential therapeutic relevance, administration of anti-VCAM1 antibody in aged mice led to increased NPC activity, reduced microglial reactivity and improved hippocampaldependent learning and memory (Fig. 6 and Extended Data Figs. 5 and 9) . Moreover, long-term genetic deletion of Vcam1 in BECs during adulthood also reduced microglial activation and resulted in increased NPC numbers in the hippocampus of aged mice ( Fig. 6d-f ). On the basis of our experimental evidence, we propose the following model: (1) factors in plasma from aged individuals, including TNF-α and IL-1β, induce BEC expression of VCAM1; (2) VCAM1 facilitates tethering, but not transmigration, of leukocytes, which sustains BEC inflammation; and (3) inflamed and activated venous and arterial VCAM1
+ BECs relay signals to the parenchyma to activate microglia, inhibit NPC activity and impair cognition (Extended Data Fig. 10 ). Naturally, future work will have to refine, revise and test other aspects of this model.
We report that VCAM1 expression on BECs, the major cell type of the BBB 40 , is upregulated during normal aging or by exposure to dialyzed plasma from aged individuals. As VCAM1 is shed constitutively by ADAM17 (refs. 20,41 ), we observe a concomitant increase in sVCAM1 levels with aging in blood ( Fig. 1) , we detected the increase with age by immunofluorescence and flow cytometry only after retro-orbital injection of fluorescently conjugated anti-VCAM1 antibody before mouse perfusion and cell processing or by using scRNA-seq (Figs.1 and 3, and Extended Data Fig. 1 ).
The circulating factors mediating the observed pro-aging effects on the brain are unknown at this point, but because we dialyzed the plasma, removing most metabolites and small molecules, we think proteins are responsible for communicating many of the circulatory signals to the brain. Indeed, circulating cytokines and chemokines with detrimental effects on the brain have increased levels in blood with advanced age 8 , and TNF-α, IL-1β and IL-4 induce expression of endothelial VCAM1 through NF-κB signaling 29, 30 , in line with our findings (Fig. 2j ). In contrast, the shed form of VCAM1 is unlikely to be a culprit, because depletion of sVCAM1 from the plasma of aged individuals did not affect its capacity to increase VCAM1 levels, activate microglia or inhibit NPC activity (Extended Data Fig. 6 ).
How then do increased levels of VCAM1 in BECs result in brain dysfunction with age, as proposed in our model? It is possible that leukocytes expressing VLA-4 bind to VCAM1 expressed on venule BECs, releasing detrimental factors toward the endothelium (as seen in atherosclerosis) and/or activating BECs via VCAM1 (refs. 51, 52 ). Indeed, ligand binding to VCAM1 can induce Ca 2+ mobilization, hydrogen peroxide production, and p38 MAPK and protein kinase C (PKC)-α activation, leading to concerted activation of endothelial cells 51, 52 . While these events are necessary for transcytosis of leukocytes, aging or plasma from aged individuals, in our hands, did not result in upregulation of ICAM1, E-selectin or P-selectin, proteins required for transcytosis. Indeed, during normal aging, leukocyte recruitment into the brain parenchyma is minimal or absent (Extended Data Figs. 7 and 8; refs. 8, 50, 53 ). Likewise, heter- + vessels. Scale bar, 100 µm. Data are shown as the mean ± s.e.m. ****P = 0.0013, P = 0.06 (PBS versus aged human plasma in mice treated with anti-VCAM1 monoclonal antibody), two-way ANOVA with Tukey's multiple-comparisons test. c,f, Representative confocal images (c) and quantification (f) in the DG of EdU and SOX2. Hoechst labels cell nuclei. Arrowheads indicate proliferating NPCs. The SGZ is outlined with white lines. Scale bar, 50 µm. n = 10 mice per group. Data are shown as the mean ± s.e.m. *P = 0.0154, two-way ANOVA with Tukey's multiple-comparisons test. d,g, Representative confocal images (d) and quantification (g) in the DG of CD68 and IBA1. Hoechst labels cell nuclei. Scale bar, 100 µm. n = 10 mice per group. Data are shown as the mean ± s.e.m. ****P < 0.0001, ***P = 0.0001, *P = 0.0407, two-way ANOVA with Tukey's multiple-comparisons test. h, Experimental design. n = 8 mice injected with PBS (r.o.), 8 mice injected with aged mouse plasma (r.o.) and IgG (i.p.), and 7 mice injected with aged moue plasma (r.o.) and anti-VCAM1 monoclonal antibody (i.p.). i,j, Quantification (i) and representative confocal images (j) in the DG of BrdU + and BrdU + SOX2 + precursor cells. The SGZ is outlined with white lines. Scale bar, 100 µm. n = 8 mice injected with PBS, 8 mice injected with aged mouse plasma and IgG, and 7 mice injected with aged mouse plasma and anti-VCAM1 monoclonal antibody. Data are shown as the mean ± s.e.m. *P = 0.0253, **P = 0.0056, ***P = 0.0041, ****P = 0.019, one-way ANOVA with Tukey's post hoc test for group comparisons. k, Quantification in the DG of the total number of surviving EdU + cells, EdU + GFAP + astrocytes and EdU + SOX2
+ GFAP + radial glia-like neural stem cells in the SGZ based on confocal images of brain sections immunostained for EdU, SOX2 and GFAP. n = 8 mice injected with PBS, 8 mice injected with aged mouse plasma and IgG, and 7 mice injected with aged mouse plasma and anti-VCAM1 monoclonal antibody. Data are shown as the mean ± s.e.m. *P = 0.011, **P = 0.0057, ***P = 0.0083, ****P = 0.049, *****P = 0.022, one-way ANOVA with Tukey's post hoc test for group comparisons. l,m, Representative confocal images (l) and quantification (m) in the GCL of EdU, DCX and NeuN. Scale bar, 100 µm. n = 8 mice injected with PBS, 8 mice injected with aged mouse plasma and IgG, and 7 mice injected with aged mouse plasma and anti-VCAM1 monoclonal antibody. Data are shown as the mean ± s.e.m. *P = 0.0399 and P = 0.0643 (aged mouse plasma + IgG versus aged mouse plasma + anti-VCAM1 monoclonal antibody), one-way ANOVA with Tukey's post hoc test for group comparisons. n, Cell fate based on co-labeling of surviving EdU + cells 4 weeks after Arrowheads indicate proliferating NPCs. The white lines outline the SGZ. Scale bar, 100 µm. n = 7 mice per group. c, Representative confocal images of CD68, IBA1 and Hoechst from the experiment described in a. Scale bar, 100 µm. n = 7 mice per group. d, Quantification in the DG of BrdU and SOX2. n = 7 mice per group. Data are shown as the mean ± s.e.m. *P = 0.0341, **P = 0.0027, two-tailed Student's t test. e, Quantification in the DG of CD68 and IBA1 from confocal images. n = 7 mice per group. Data are shown as the mean ± s.e.m. ***P = 0.0005, **P = 0.0026, *P = 0.0354, two-tailed Student's t test. f, Experimental design for conditional deletion of Vcam1 in young (2-month-old) mice followed by aging to 18 months. n = 8 mice per group. g, Quantification of total BrdU + proliferating cells and BrdU
+ NPCs in immunostained sections of DG. n = 8 mice per group. Data are shown as the mean ± s.e.m. **P = 0.0075, *P = 0.0263, two-tailed Student's t test. h, Quantification in the DG of CD68 and IBA1. Hoechst labels cell nuclei. n = 8 mice per group. Data are shown as the mean ± s.e.m. **P = 0.0068, *P = 0.0169, two-tailed Student's t test. i,j, Escape latency on days 1-5 from the Barnes maze (i) and percentage of time spent exploring objects in the novel object placement task (j) for IgG-treated young adult C57BL/6 mice (5 months old; n = 15) and IgG-treated aged mice (17 months old; n = 15) or aged mice treated with anti-VCAM1 monoclonal antibody (17 months old; n = 15) . All mice received intraperitoneal injections every 3 d for 3 weeks before initiation of the behavioral studies and throughout the duration of the studies. *P = 0.0217, **P < 0.01, ***P < 0.001, ****P < 0.0001, two-way repeated-measures ANOVA with Bonferroni's post hoc test for time × group comparisons and one-way ANOVA with Tukey's post hoc test for group comparisons. Data are shown as the mean ± s.e.m. k, Quantification of freezing behavior in fear conditioning contextual trials with 23-month-old C57BL/6 mice injected with anti-VCAM1 monoclonal antibody or IgG every 3 d for 1 month. Averages from trials 3-5 are shown. n = 7 PBS-, n = 12 IgG-and n = 13 anti-VCAM1-treated mice. **P = 0.0075, *P = 0.0265, one-way ANOVA with Tukey's post hoc test for group comparisons. Data are shown as the mean ± s.e.m.
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Finally, in the third step of our model, we propose that activated VCAM1 + BECs function as relay stations of circulatory signals (or cells) communicating information as part of the neurovascular unit to surrounding glia and neurons. Intriguingly, we observe VCAM1 expression in only a small subset of BECs, even after LPS stimulation (Figs. 1 and 3, and Extended Data Figs. 1, 3 and 8) . scRNA-seq of isolated hippocampal BECs identified three unique subpopulations, in line with a recent scRNA-seq study of mouse brain endothelium 26 : (1) Vcam1-negative capillaries expressing characteristic BBB genes related to transport and metabolism, (2) Vcam1-positive arterial BECs enriched in Notch signaling markers and (3) Vcam1-positive venous BECs expressing inflammatory gene transcripts ( Fig. 2 and Extended Data Figs. 1 and 2 ). Considering that even young, healthy mice contain VCAM1-expressing subpopulations of BECs, we hypothesize that these cells function as the above-mentioned relay stations and environmental sensors. In addition to the canonical roles of VCAM1 in leukocyte extravasation and inflammation in venous BECs, Vcam1-positive arterial BECs are enriched for transcripts related to Notch signaling and vascular remodeling. We speculate that the regenerative effect of Vcam1 deletion in young mice ( Fig. 4) and, possibly, the perturbation of homeostasis in the SVC neural stem cell niche 35, 55 (see discussion below) may involve these specialized Vcam1-positive arterial BECs.
Given that the transcriptional profile of BECs changes drastically with age, exhibiting an overall activated, proinflammatory signature ( Fig. 1) , it could be expected that BBB function is different between young and aged mice. Indeed, it is generally agreed that the ultrastructural composition, the activity of the neurovascular unit and the transport of various types of molecules change with age 55 . Montagne et al. used advanced dynamic contrast-enhanced magnetic resonance imaging in brains in living humans and reported that the BBB deteriorates and becomes more permeable in the aged hippocampus 56 . Although studies focused on normal aging remain limited, Bien-Ly et al. showed that multiple mouse models of AD have limited uptake of therapeutic antibodies owing to intact BBB and limited permeability 57 . Although fixable large and non-fixable small dextran tracers indicate no overt leakage of the BBB with aging or following genetic Vcam1 deletion in our studies (Extended Data Fig. 7a-d) , we observed some age-related differences in tight junction gene expression with aging ( Fig. 1b and Extended Data Fig.1e,r) . In conclusion, it is possible that VCAM1 contributes to the overall regulation of BBB function with aging, but additional studies involving more refined methods will be required to test this possibility.
Apart from the new role in hippocampal aging and function we describe here, VCAM1 is required under non-pathological conditions for type B neural stem cell anchoring to the neurogenic niche of the SVZ 35 , where it is highly expressed in endothelial cells of the lateral ventricles and epithelial cells of the choroid plexus 35, 58 . Kokovay et al. showed that VCAM1 expression increases in the lateral ventricles as a result of increased inflammatory cytokine signaling, leading to production of reactive oxygen species and restriction of neural stem cell proliferation and lineage progression in the SVZ 35 . Intraventricular infusion of anti-VCAM1 antibody activated type B neural stem cells to a proliferative state 35 . Additionally, it was recently shown that VCAM1 expression in radial glial cells is necessary for embryonic neurogenesis and development of the SVZ neurogenic niche 59 . Although this seems to contradict our findings, we indeed observed that genetic deletion of Vcam1 in young Cre + mice in which Vcam1 was flanked by loxP sites resulted in a reduction in baseline NPC activity. Thus, VCAM1 seems to have dual roles in regulating adult NPC activity, supporting a homeostatic role related to anchoring of stem cells in their niche, as well as a role in aging-related inflammation, which inhibits NPC activity. In other words, genetic ablation of brain endothelial and epithelial Vcam1 in young animals may reduce NPC activity owing to depletion of the quiescent neural stem cell population. Increased VCAM1 with aging and inflammation, on the other hand, may reduce NPC activity by restricting neural stem cell activation and lineage progression. Additionally, activated microglia might also be directly inhibiting NPC activity via secretion of inflammatory soluble factors 60 .
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-019-0440-4. Cell Rep. 10, 1158 -1172 (2015 /J) mice purchased from Jackson Laboratory. Male mice were used for plasma treatment studies following treatment with tamoxifen (an estrogen modulator). Aged (greater than 12 months of age) C57BL/6J males and females were obtained from the National Institute on Aging (NIA), and young C57BL/6J males (2-4 months of age) were purchased from Jackson Laboratory and Charles River. BALB/c NctrNpc1 m1N /J 9-week-old homozygous males and females were generated by breeding heterozygous mice acquired from Jackson Laboratory. Seventeen-to 18-month-old male and female wild-type and Grn -/-mice (B6.129S4(FVB)-Grn tm1.1Far /Mmja) were bred and aged in house but originally acquired from Jackson Laboratory. These transgenic strains were bred and aged in house. All mice lived under a 12-h light/12-h dark cycle in pathogen-free conditions with free access to dry feed and water, in accordance with the Guide for Care and Use of Laboratory Animals of the National Institutes of Health. The status of in-house-aged mice was monitored every 2-3 months via weight and physical checks; young (2-to 4-month-old) mice weighed 20-30 g and aged (greater than 12 months of age) mice weighed 40-50 g. Mice found to have health issues were excluded from studies and assessed by the in-house veterinary medical officer. All animal care and procedures complied with the Animal Welfare Act and were in accordance with institutional guidelines and approved by the VA Palo Alto Committee on Animal Research and the institutional administrative panel of laboratory animal care at Stanford University.
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Human blood samples. Human blood samples from healthy males in the age ranges of 18-25 and 65-74 years were anonymously donated to the Stanford Blood Center, Palo Alto. Blood was centrifuged at 1,600g for 10 min at 4 °C, and plasma was collected and centrifuged again at 1,600g for 10 min at 4 °C. Plasma was dialyzed by using cassettes (Slide-A-Lyzer Dialysis Cassettes, 3.5k MWCO, 12 ml (Fisher, PI 66110)) in 4 liters of PBS with a stir bar for 45 min at room temperature, with fresh PBS added every 20 min. Cassettes were transferred to 4 liters of fresh PBS with a stir bar for overnight dialysis at 4 °C. Plasma samples from five aged individuals >65 years old were pooled together for aged human plasma injections or in vitro studies. Plasma samples anonymously donated by five young adults <25 years old were pooled together for in vitro studies. Plasma was aliquotted to prevent more than one freeze-thaw cycle and stored at −80 °C until further use.
Plasma collection, dialysis and processing. Mouse. Approximately 500 µl of blood was drawn from the heart in 250 mM EDTA (Sigma-Aldrich, CAS no. 60-00-4) and immediately transferred to ice. Blood was centrifuged at 1,000g for 10 min at 4 °C. Plasma was collected and immediately snap frozen on dry ice and stored at −80 °C until further processing. Plasma was dialyzed in 4 liters of 1× PBS (51226, Lonza) stirred at room temperature. Plasma was transferred to 4 liters of fresh 1× PBS after 45 min and then again 20 min later. After the second transfer, plasma was dialyzed overnight at 4 °C in 4 liters of stirred 1× PBS. Plasma from 7-9 mice was pooled for injections.
Human. Donor plasma (healthy males, aged 18-25 or 65-74 years) was purchased from the Stanford Blood Bank. Human plasma was dialyzed as described for mouse plasma (see above). Plasma from five individuals for an age group was pooled for injections.
Proteomics (human plasma, VCAM1 analysis). Britschgi et al. measured plasma factors in cognitively normal individuals and patients with AD by multiplex assay, which measured 74 cytokines, chemokines, growth factors and related proteins in plasma by using bead-based multiplex immunoassays as described 9 . We used the raw plasma data generated in which low values were replaced with the lowest detectable value measured in patients with AD or controls (Data 4 of the supplementary data) and focused our analysis on subjects who were cognitively normal (n = 118 subjects; 59 males and 59 females). The age range was between 50 and 88 years with a median age of 68 years. We replaced QNS (quantity not sufficient) values in the dataset by NA and log 10 transformed the data. To measure the strength of the relationships between age and levels of plasma factors, we used the R Segmented package 64, 65 to calculate Spearman's correlation coefficients. To visualize the changes in levels of plasma factors with aging, mean value per decade was calculated for each plasma factor and hierarchical clustering was applied.
Primary BEC isolation for bulk and single-cell RNA-seq. Primary BEC isolation and quantification of CD31 +
VCAM1
+ cells. BEC isolation was conducted as recently described 66 . Briefly, mice were anesthetized with Avertin and perfused following blood collection. After thoroughly dissecting the meninges, the cortices and hippocampi were collected, minced and digested with the neural dissociation kit according to kit instructions (Miltenyi, ). Brain homogenates were filtered through a 35-µm filter in HBSS and centrifuged pellets were resuspended in 0.9 M sucrose in HBSS followed by centrifugation for 15 min at 850g at 4 °C to separate the myelin. This step was repeated for better myelin removal.
Cell pellets were eluted in FACS buffer (0.5% BSA in PBS with 2 mM EDTA) and blocked for 10 min with Fc preblock (CD16/CD32, BD, 553141), followed by staining for 20 min with anti-CD31-APC (1:100; BD, 551262), anti-CD45-FITC or anti-CD45-APC/Cy7 (1:100; BD Pharmingen, clone 30-F11, 553080; BioLegend, 103116), and anti-Cd11b-BV421 (1:100; BioLegend, clone M1/70, 101236). Dead cells were excluded by staining with propidium iodide (PI) solution (1:3,000; Sigma, P4864). Flow cytometry data were acquired and cell sorting was performed on an ARIA II (BD Biosciences) with FACSDiva software (BD Biosciences). FlowJo software was used for further analysis and depiction of the gating strategy. Gates are indicated by framed areas. Cells were gated on forward (FSC, size) and side (SSC, internal structure) scatter. FSC-A and FSC-W blotting was used to discriminate single cells from cell doublets or aggregates. PI + dead cells were excluded. CD11b
+ and CD45 + cells were gated to exclude monocytes/macrophages and microglia. CD31
-cells were defined as the BEC population and were sorted directly into RNAlater (Life Technologies, AM7020) and stored at −80 °C until further processing. If mice were injected with fluorescently labeled anti-mouse VCAM1-DL488 as described above, CD45 was stained in the APC/Cy7 channel and CD31
+ cells were also gated in the APC and FITC channels.
Anti-VCAM1 antibody in vivo retro-orbital injections to label CD31 + VCAM1
+ BECs in C57BL/6J mice. For gating of VCAM1 + cells, mice were injected with LPS derived from Salmonella enterica serovar Typhimurium (Sigma, L6511), intraperitoneally at 1 mg LPS per kg body weight at three successive time points: 0 h, 6 h and 24 h (ref. 67 ). Control mice were injected with body-weightcorresponding volumes of PBS. Experimental mice received intraperitoneal and subcutaneous injections of sterile 0.9% saline with 5% glucose to ensure hydration and stable glucose levels during the procedure. Mice received a third LPS injection followed by retro-orbital injections of either 100 µg fluorescently labeled (DyLight 488, Thermo Scientific, 53025) InVivoMAb anti-mouse CD106 (VCAM1, clone M/K-2.7, BioXcell, BE0027) or fluorescently labeled rat IgG1 isotype antibody (clone HRPN, BioXcell, BE0088). Two hours after the last LPS injection (26 h), mouse brains were collected for BEC isolation and flow cytometry analysis.
Healthy young (3-month-old), aged (19-month-old) or plasma-injected (retroorbitally) young mice were similarly injected (retro-orbitally) with fluorescently labeled anti-VCAM1 monoclonal antibody and gated for flow cytometry analysis of CD31 +
VCAM1
+ cells from cortices and hippocampi. Gates are based on positive-control LPS-stimulated mice injected (retro-orbitally) with anti-VCAM1 antibody or IgG control.
RNA sequencing. Bulk RNA-seq. Mouse hippocampi and cortices (two pooled brains per sample; n = 6 young (3-month-old C57BL/6J male) samples or n = 6 aged (19-month-old C57BL/6J male) samples were dissected using the neural dissociation kit (Miltenyi, 130-092-628) following perfusion. BECs (average of 81,000 CD31 + CD45 -CD11b -cells per pooled sample) were isolated via multichannel flow cytometry and sorted directly into RNAlater as described above. Frozen cells were thawed to room temperature before centrifugation for 10 min at 1,000g. Total RNA was isolated from the cell pellets with the RNeasy Plus Micro kit (Qiagen, 74034). RNA quantity and quality were assessed by Agilent 2100 Bioanalyzer (Agilent Technologies). All samples passed a quality-control threshold (RIN ≥ 8.5) to proceed to library preparation and RNA-seq.
Total mRNA was transcribed into full-length cDNA by using the Smart-Seq v4 Ultra-Low-Input RNA kit from Clontech according to the manufacturer's instructions. Samples were validated with an Agilent 2100 Bioanalyzer and Agilent High-Sensitivity DNA kit. Full-length cDNA (150 pg) was processed with the Nextera XT kit from Illumina for library preparation according to the manufacturer's protocol. Library quality was verified with an Agilent 2100 Bioanalyzer and Agilent High-Sensitivity DNA kit. Sequencing was carried out with an Illumina HiSeq 2000 (paired-end, 2 × 100 bp) sequencer.
FastQC v0.11.2 was used to provide quality-control checks on the raw RNA-seq data. STAR v2.4.2a was used to align the RNA-seq reads to the mouse reference genome (mm9). The Cuffdiff v2.2.1 statistical package was used to perform differential expression analysis for RNA-seq on the basis of gene and transcript abundance measurements in terms of FPKM, as previously described 68 . The R v3.2.2 statistical package and CummeRbund v2.12.1 R/Bioconductor package were used for visualization of the various output files of the Cuffdiff differential expression analysis including visualization of changes in gene transcripts with age. FPKM values for genes and transcripts were tabulated, and Cluster v3.0 was used to perform hierarchical clustering and cluster analysis. Java TreeView v1.1.6 was used to visualize the output files from hierarchical clustering in the form of heat maps displaying genes that were differentially up-or downregulated in BECs from aged versus young mice. The gene set enrichment analysis (GSEA; v2.2.0) tool was used to determine whether GO and pathway gene sets showed statistically significant, concordant differences between BECs from young and aged mice.
Single-cell RNA-seq of VCAM1
+ -enriched BECs. Four young (3-month-old) and four aged (19-month-old) C57BL/6J males were injected (retro-orbitally) with fluorescently labeled anti-VCAM1 monoclonal antibody 2 h before they were killed and cells were gated for single-cell isolation of CD31 + VCAM1 + cells from pooled hippocampi following perfusion. Gates were based on positive-control Articles NATurE MEDiCiNE LPS-stimulated mice injected with fluorescently labeled anti-VCAM1-DL488 monoclonal antibody or IgG-DL488 control antibody.
Hippocampi (from both hemispheres) were pooled from four young (3-monthold) or four aged (19-month-old) C57BL/6J males, sorted into lysis buffer in 96-well plates and then snap frozen and stored at −80 °C until RNA extraction and library preparation. Two 96-well plates per group contained BECs that were 50% enriched for high expression of VCAM1 on the basis of flow cytometry gating; unbiased CD31 + cells were also collected into two 96-well plates per group.
cDNA synthesis, library preparation and sequencing. Cell lysis and cDNA synthesis were performed with the Smart-Seq2 protocol as described previously 68, 69 , with some modifications. After cDNA amplification (23 cycles), cDNA concentrations were determined via capillary electrophoresis and cells were cherry-picked to improve quality and decrease cost of sequencing. Cell selection was done through custom scripts and simultaneously normalized cDNA concentrations to ~0.2 ng µl -1 per sample, by using the TPP Labtech Mosquito HTS and Mantis (Formulatrix) robotic platforms. Libraries were prepared with Illumina Nextera XT kits following the manufacturer's instructions. Libraries were then sequenced on a NextSeq instrument (Illumina) by using 2 × 75 bp paired-end reads and 2 × 8 bp index reads with a 200-cycle kit (Illumina, 20012861) and pooled by the Mosquito liquid handler. Library quality was assessed via capillary electrophoresis on a Fragment Analyzer (AATI) and quantified by qPCR. Samples were sequenced at an average of 700,000 reads per cell.
Bioinformatics pipeline. Sequences from the NextSeq were demultiplexed with bcl2fastq, and reads were aligned to the mm10 genome augmented with ERCC sequences, by using STAR version 2.5.2b. Gene counts were made with HTSeq version 0.6.1p1. We applied standard algorithms for cell filtration, feature selection and dimensional reduction. First, genes appearing in fewer than three cells, cells with fewer than 300 genes and cells with fewer than 50,000 reads were excluded from the analysis. Of the remaining cells, those with more than 30% of reads as ERCC sequences or more than 5% mitochondrial or 3% ribosomal sequences were also excluded. Counts were log normalized (log(1 + counts per million)) and then scaled via linear regression against the number of reads, the percentage mapping to ribosomal genes and the percentage mapping to mitochondrial genes. To select for relevant features, genes were first filtered to a set of 3,000 with the highest positive and negative pairwise correlations. Genes were then projected into low-dimensional principal-component space with robust principal-component analysis (rPCA). Single-cell principalcomponent scores and gene loads for the first 20 principal components were analyzed with the Seurat package in R. Briefly, a shared-nearest-neighbor graph was constructed on the basis of the Euclidean distance metric in principalcomponent space and cells were clustered via the Louvain method. Cells and clusters were then visualized with 3D t-distributed stochastic neighbor embedding on the same distance metric. Differential gene expression analysis was done by applying the Mann-Whitney U test to the BEC clusters obtained by using unsupervised clustering. P values were adjusted via the false-discovery rate (FDR) or Bonferroni method. All graphs were generated and analyses performed in R.
GeneAnalytics and GeneCards packages offered by the GSEA tool were used for GO pathway analysis and classification of enriched genes in each subpopulation.
Cell culture. For all studies, Bend.3 cells (a gift of the Butcher laboratory; purchased from the ATCC) were used. Bend.3 cells are immortalized brain endothelial cells isolated from BALB/c mice (CRL-2299, ATCC) 70 . These cells were seeded at 40,000 cells cm -2 in MCDB-131 HUVEC medium (10372019, Life Technologies) supplemented with 15% endotoxin-free FBS (SH30071, GE Healthcare Life Sciences), 1% sodium pyruvate (11360070, Life Technologies), 1% heparin (H4784, Sigma-Aldrich), 1% penicillin-strconcentrations were determined via capillaryeptomycin (1786396, Life Technologies), 1% nonessential amino acids (11140050, Life Technologies), 1% l-glutamine (2 mM; Fisher Scientific, Glutamax supplement, 35050061) and 1% 100 mg ml -1 sodium bicarbonate (S5761, Sigma-Aldrich). To confirm cell morphology and tight and adherens junctions, we stained with antibodies to β-catenin (Millipore, 05-665), claudin-5 (Thermo Scientific, 34-1600) and VE-cadherin (Santa Cruz Biotechnology, sc-6458) after fixation in cold methanol for 10 min followed by three washes in PBS and incubation for 1 h in TBS++. Cells were maintained in a humidified 5% CO 2 incubator at 37 °C. Cells at low density were fed with fresh medium every other day; cells at high density were fed every day. Cells were split 1:2 or 1:3 at ≥80% confluency.
Primary BEC cultivation was based on a previously described procedure 71 . For primary BEC cultivation, cells were resuspended in endothelial cell growth medium (20% FBS, 2 mM l-glutamine, 2 mM penicillin-streptomycin, 1× MEM non-essential amino acids, 0.1 mg ml -1 heparin, 1 mM sodium pyruvate, 1 mg ml -1 sodium hydrogen carbonate, 0.05 mg ml -1 ECGS in MCDB-131) and seeded on tissue culture plates coated with 1 mg ml -1 rat tail collagen (BD Biosciences, 354236). After 24 h, 4 µg ml -1 puromycin (Santa Cruz Biotechnology, sc-108071A) was added for 48 h to remove potentially contaminating cells 72 .
In vitro cytokine treatment and flow cytometry analysis. Bend.3 cells plated in six-well plates (seeded at 400,000 cells per well) were serum starved for 1 h followed by overnight treatment for 16 h with recombinant TNF-α (10 ng ml -1 ), IL-1β (10 ng ml -1 ) or IL-6 (30 ng ml -1 ). After overnight treatment, medium was aspirated and cells were washed once with PBS. Cells were detached with 700 μl of accutase (A1110501, Life Technologies) for 5 min and the reaction was stopped by resuspending cells in 2 ml of PBS. Cells were centrifuged for 5 min at 300 r.c.f. and medium was aspirated. After centrifugation, cells were resuspended in PBS for one wash followed by blocking for 30 min in FACS buffer (DPBS + 1 g liter -1 glucose + 30 mM sodium pyruvate + 2% BSA with 2 mM EDTA). Following centrifugation, cells were resuspended in 100 μl per sample of FACS buffer. Fc blocking antibody (553142, BD Pharmingen) was added for 10 min followed by addition of each antibody (1:50). Samples were incubated in antibodies for 30 min to 1 h with shaking at room temperature and covered from light. After one wash with FACS buffer, cells were resuspended in 500 μl of FACS buffer and transferred to flow tubes for analysis. Bend.3 cells were stained with a conjugated anti-CD31 antibody (CD31-APC; 551262, BD Pharmingen) and an anti-VCAM1 antibody (BE0027, BioXcell) fluorescently conjugated with the DyLight 488 Conjugation kit according to the manufacturer's instructions (53024, Thermo Scientific). FSC-A and FSC-W blotting was used to discriminate single cells from cell doublets and aggregates. PI + dead cells were excluded. Cells were gated on the basis of positive staining for CD31 and VCAM1 in comparison to n -1 control staining and IgG isotype control staining.
In vitro VCAM1 analysis following plasma administration. Immunofluorescence analysis. Bend.3 cells or primary BECs were seeded in eight-well chamber slides (154534, Thermo Scientific) overnight with 40,000 cells cm -2 . Cells were serum starved for 1 h via incubation in DMEM with no added supplements (11965-092, Gibco), followed by treatment in DMEM with 10% pooled and dialyzed serum derived from plasma from young (25 years or younger) or aged (65 years or older) humans (Bend.3 cells) or plasma from young (3-month-old) or aged (19-monthold) mice (primary BECs and Bend.3 cells) for 16 h. Plasma was warmed to 37 °C and filtered through a 22-µm filter before being added to cells. The following day, cells were fixed in cold 4% paraformaldehyde for 10 min, followed by three 5-min PBS washes and blocking for 1 h in TBS with 3% donkey serum and 0.25% Triton X-100 (TBS++). Cells were blocked in TBS++ and primary antibody (1:250) overnight: anti-VCAM1 (ab19569, Abcam) and anti-VE-cadherin (sc-6458, Santa Cruz Biotechnology). Cells were blocked in TBS++ and secondary antibody TNF-α dosage response. Bend.3 cells were seeded overnight as described above and serum starved for 1 h before being cultured for 24 h in varying concentrations of TNF-α (5 ng ml -1 to 156.25 pg ml -1 ) in DMEM, followed by staining with antibodies to CD31 and VCAM1 and flow cytometry analysis.
In vitro flow cytometry analysis. Bend.3 cells were serum starved for 1 h followed by overnight treatment for 16 h with 10% plasma-derived serum from young or aged mice or humans, as described above for in vitro VCAM1 analysis. After overnight treatment with plasma, medium was aspirated and cells were washed once with PBS. Cells were detached with 700 µl of accutase (A1110501, Life Technologies) for 5 min and the reaction was stopped by resuspending cells in 2 ml of PBS. Cells were centrifuged for 5 min at 1,100 r.p.m., medium was aspirated and cells were resuspended in 1 ml per well of PBS with 4% paraformaldehyde (diluted with 8 ml of PBS) and fixed on ice for 10 min. After centrifugation at 1,100 r.p.m. for 5 min, cells were resuspended in PBS for one wash followed by blocking for 30 min in FACS buffer (PBS + 2% BSA with 2 mM EDTA). Following centrifugation, cells were resuspended in 100 µl per sample of FACS buffer. Fc blocking antibody (553142, BD Pharmingen) was added for 10 min followed by addition of each antibody. Samples were incubated in antibodies for 30 min to 1 h on ice. After two washes with FACS buffer, cells were resuspended in 500 µl of FACS buffer and transferred to flow tubes for analysis. Bend.3 cells were stained with a conjugated anti-CD31 antibody (CD31-APC) (551262, BD Pharmingen), an anti-VCAM1 antibody (BE0027, BioXcell) conjugated with the DyLight 488 Conjugation kit according to the manufacturer's instructions (53024, Thermo Scientific) and rat anti-mouse E-selectin-DL405 (clone RB40.34, a gift of the Butcher laboratory). Plasma-treated Bend.3 cells were also stained with anti-CD31-PE/Cy7 (102418, BioLegend), anti-ICAM1-DL594 (clone YN1/1.7.4, a gift of the Butcher laboratory) and anti-P-selectin-DL405 (clone 10E9.6, a gift of the Butcher laboratory). Cells were gated on forward (FSC, size) and side (SSC, internal structure) scatter. FSC-A and FSC-W blotting was used to discriminate single cells from cell doublets and aggregates. PI + dead cells were excluded. CD31 + cells were defined as BECs.
In vivo mouse studies. Parabiosis. Isochronic and heterochronic parabiosis was performed as described 8 . In brief, mirror-image incisions through the skin were made on the left and right flanks of mice and shorter incisions were made through the abdominal wall. Parabionts were sutured together at their adjacent peritoneal openings. The parabionts' elbow and knee joints were also sutured together and the skin of each mouse was stapled together. For 1 week during recovery after surgery, Articles NATurE MEDiCiNE each parabiont mouse received daily subcutaneous injections of Baytril antibiotic solution (5 µg per gram of body weight in saline to give a volume of approximately 1% of the weight of each mouse) and buprenorphine (0.1 µg ml -1 , 0.05 mg per kg) as well as physiological saline (0.9%) for pain relief, prevention of infection and hydration and were monitored regularly.
In vivo cytokine injections. For low-dose cytokine injections, young (2.5-monthold) C57BL/6 littermates were injected every other day (0.08 mg per kg retroorbitally) with recombinant proinflammatory cytokines (TNF-α, IL-1β or IL-6) for 5 d (n = 4 mice per group for six groups). Mice received BrdU (100 mg per kg intraperitoneally) twice daily beginning on the fifth day after the start of cytokine treatment. On the sixth day, mice were pulsed with the last BrdU and cytokine injections. All mice were also injected (retro-orbitally) with 0.05 mg of fluorescently labeled (DyLight 488, Thermo Scientific, 53025) rat anti-mouse-VCAM1 antibody (clone M/K-2.7, BioXcell, BE0027) before perfusion. Two hours after the final injections, mice were anesthetized with Avertin followed by PBS perfusion.
For high-dose acute cytokine treatment, young (2.5-month-old) C57BL/6 littermates were injected (0.4 mg per kg retro-orbitally) with TNF-α, IL-1β or PBS control (n = 3-4 mice per group for four groups). Mice were injected (retro-orbitally) with 0.05 mg of fluorescently labeled (DyLight 488, Thermo Scientific, 53025) rat anti-mouse-VCAM1 antibody (clone M/K-2.7, BioXcell, BE0027) approximately 16 h later. Two hours after antibody injections, mice were anesthetized with Avertin followed by PBS perfusion. Full information on the cytokines used can be found in Supplementary Table 5 .
C57BL/6 mice: plasma injections in young mice. Young (3-month-old) C57BL/6J male mice were treated with seven injections of dialyzed and pooled plasma from young (3-month-old) or aged (18-month-old) mice (150 µl retro-orbitally), derived from 8-10 mice per pooled plasma sample. Mice were treated acutely over 4 d, with two injections per day separated by 10-12 h. During both the morning and evening injections on day 3 and the morning injection on day 4, mice were pulsed with BrdU to label proliferating cells (100 mg per kg intraperitoneally; B5002-5G, Sigma-Aldrich). Mice received a seventh plasma injection along with BrdU on day 4 followed by perfusion 3 h after the last injection.
C57BL/6 mice: aged mice treated with anti-VCAM1 or anti-VLA-4 monoclonal
antibody. Aged (16-month-old) C57BL/6J mice received intraperitoneal injections of anti-VCAM1 monoclonal antibody (BE0027, BioXcell) or IgG isotype control (9 mg per kg) every 3 d for a total of seven injections. Mice also received BrdU daily (100 mg per kg intraperitoneally) for the last 6 d before perfusion 24 h after the last BrdU injection and 48 h after the last antibody injection.
Similarly, aged (16-month-old) C57BL/6J mice received intraperitoneal injections of anti-VLA-4 monoclonal antibody (BE0071, BioXcell) or IgG isotype control (9 mg per kg) every 3 d for a total of seven injections. Mice also received BrdU daily (100 mg per kg intraperitoneally) for the last 6 d before perfusion 24 h after the last BrdU injection and 48 h after the last antibody injection.
C57BL/6 mice: young mice treated with anti-VCAM1 monoclonal antibody and aged plasma injections.
Young (3-month-old) C57BL/6J male mice were treated with nine injections of dialyzed and pooled plasma (150 µl retro-orbitally) from aged (18-month-old) mice, derived from 8-10 mice per pooled plasma sample. Mice also received intraperitoneal injections of anti-VCAM1 monoclonal antibody or IgG isotype control (9 mg per kg) every 3 d for a total of nine injections. Mice were injected with PBS as a baseline control. Before the start of the experiment, mice received daily EdU (Invitrogen, E10415) injections (100 mg per kg intraperitoneally) for 4 d to label newly born surviving cells. Mice were treated over 4 weeks, with one injection every third day for a total of nine injections. Starting on day 23 after the first injection of plasma and antibody, mice received daily injections of BrdU (100 mg per kg intraperitoneally; B5002-5G, SigmaAldrich) to label proliferating cells for 4 d followed by perfusion 24 h after the last BrdU injection.
EAE was induced in young wild-type C57BL/6J (4-month-old) female mice as previously reported 73 . NSG mice: long-term plasma treatment. NSG mice received PBS or pooled plasma from aged humans (AHP; >65 years, dialyzed plasma from five individuals pooled, 150 µl per injection retro-orbitally) every 3 d for 3 weeks, totaling seven injections. They also received daily EdU injections (150 mg per kg intraperitoneally) for 3 d, beginning 2 weeks after plasma treatment, followed by daily BrdU injections (150 mg per kg intraperitoneally) beginning on day 18 for 3 d followed by perfusion. n = 6-7 mice per group. NSG mice: acute plasma treatment. NSG mice received PBS or pooled plasma from aged humans (AHP; >65 years, dialyzed plasma from five individuals pooled, 150 µl per injection retro-orbitally) twice daily in the morning and evening 10-12 h apart for seven total injections. They also received EdU (150 mg per kg intraperitoneally) 16 h and 4 h before perfusion. n = 5 mice per group. NSG mice: acute plasma paradigm with anti-VCAM1. Three-month-old NSG mice received rat anti-mouse-VCAM1 monoclonal antibody or rat IgG isotype control (9 mg per kg intraperitoneally) on day 0 and day 3. Mice were given retro-orbital injections (150 µl) of plasma from aged humans (AHP; >65 years, pooled from five individuals) or PBS as control twice daily for seven total injections. Mice were pulsed with EdU (100 mg per kg intraperitoneally) 16 h and 2 h before perfusion to label proliferating cells.
NSG mice: long-term plasma paradigm with anti-VCAM1
. NSG mice received injections with pooled plasma from aged humans (AHP; >65 years, 150 µl, retro-orbitally) every 3 d for seven total injections. In addition, mice received intraperitoneal injections of an anti-VCAM1 blocking monoclonal antibody or IgG isotype control (9 mg per kg) every 3 d for a total of seven injections. They also received daily BrdU injections (150 mg per kg intraperitoneally) for 4 d beginning on day 16. NSG mice: treatment with sVCAM1-depleted plasma. sVCAM1 was immunoprecipitated from the pooled plasma of aged humans (65-74 years of age, n = 5) by using superparamagnetic microbeads conjugated to a mouse anti-human-VCAM1 antibody (BBA5, Novus Biologicals) or monoclonal mouse anti-humanIgG antibody (MAB002, R&D Systems) as a control. To first conjugate Dynabeads to the anti-IgG or anti-VCAM1 antibody, 500 µl (0.5 mg ml -1 ) of antibody was added to 25 mg of Dynabeads and beads were incubated on a rotator overnight at 37 °C and prepared according to the instructions in the manual (14311D, Thermo Scientific). The following day, 8 mg of conjugated anti-VCAM1 monoclonal antibody bound to Dynabeads or an equal amount of anti-IgG monoclonal antibody bound to Dynabeads was added to aliquots of 0.5 ml of dialyzed pooled human plasma and samples were incubated at 4 °C with rotation overnight. Depleted plasma was collected the next day and magnetic VCAM1-saturated Dynabeads were removed with a magnetic bar through serial transfers of the plasma to new tubes. Plasma was stored at −80 °C until mouse treatment.
Following pulldown of sVCAM1, pooled depleted plasma from aged humans (IgG versus sVCAM1 depleted) or saline (200 µl per mouse) was injected retroorbitally into young (4-month-old) NSG mice (n = 7-8 mice per group) twice daily for 4 d for seven total injections. Mice were also injected with BrdU (100 mg per kg intraperitoneally) starting on the third day. Mice were anesthetized with Avertin followed by saline perfusion on the fourth day of treatment, 4 h after the third BrdU and seventh plasma injections. One mouse per group received intra-orbital injections of 100 µg of fluorescently labeled (DyLight 488, Thermo Scientific, 53025) InVivoMAb anti-mouse-CD106 antibody (VCAM1, clone M/K-2.7, BioXcell, BE0027) and fluorescently labeled (DyLight 550, Thermo Scientific, 84530) rat anti-mouse-MECA-99 antibody (a gift of the Butcher laboratory) 3 h before perfusion. BEC isolation was based on a recently described procedure 74 . Briefly, mice were killed with carbon dioxide asphyxiation followed by cervical dislocation. Mouse brains were carefully removed from the skull and stored on ice in buffer A (153 mM NaCl, 5.6 mM KCl, 1.7 mM CaCl 2 , 1.2 mM MgCl 2 , 15 mM HEPES; 10 mg ml -1 BSA fraction V). After thoroughly dissecting the meninges, cortices and hippocampi were collected and washed several times in buffer A before the tissue was minced and centrifuged at 300g for 7 min at 4 °C. The pellet was digested in a 1:1:1 mix of tissue, buffer A and 0.75% collagenase II (Millipore, C2-22) at 37 °C for 50 min. The tissue was homogenized by thorough shaking after 25 and 50 min of digestion and repetitive up-and-down pipetting of the cell solution at the end of digestion. The enzymatic reaction was stopped by adding buffer A. After centrifugation (300g, 7 min, 4 °C), the pellet was carefully resuspended in PBS containing 25% BSA (Fisher Scientific, BP1600-1) and centrifuged at 1,000g for 30 min at 4 °C to separate the myelin and to enrich for capillary fragments. To deplete red blood cells, the pellet was incubated in Red Blood Cell Lysis Buffer (Sigma, R7757) for 1.5 min at room temperature with occasional shaking, followed by a wash step in buffer A and centrifugation (300g, 7 min, 4 °C). For the second digestion, the pellet was resuspended in buffer A containing 1 mg ml -1 collagenase/ dispase (Roche, 11097113001) and the mixture was incubated at 37 °C for 13 min. DNase I (1 μg ml -1 ; Sigma, 10104159001) was added for two additional minutes. To quench the reaction, buffer A was added and cells were centrifuged at 300g for 7 min at 4 °C.
For flow cytometry, enriched BECs were labeled by standard protocols with fluorochrome-conjugated antibodies (listed in the antibodies section) in HBSS (Thermo Fisher) containing 10% FBS for 30 min on ice. Dead cells were excluded by staining with PI solution (1:3,000; Sigma, P4864). Background fluorescence was determined by the 'fluorescence-minus-one' method, and for VCAM1 a specific IgG1 isotype control antibody was used. Flow cytometry data were acquired on Articles NATurE MEDiCiNE an ARIA II (BD Biosciences) with FACSDiva software (BD Biosciences). FlowJo software (TreeStar) was used for further analysis.
Cells were gated on forward (FSC, size) and side (SSC, internal structure) scatter. FSC-A and FSC-W blotting was used to discriminate single cells from cell doublets and aggregates. PI uptake indicated dead cells, which were excluded. Cells negative for CD11a, CD11b, CD45 and Ter-119 were gated to exclude erythrocytes, monocytes/macrophages and microglia. CD13 and ACSA-2 staining were applied to exclude pericytes and astrocytes, respectively. CD31
+ MECA-99 + cells were defined as the BEC population.
Conditional Vcam1-knockout mice: basal NPC activity. Young (4-month-old) heterozygous Cre + or Cre -littermates were injected once daily with tamoxifen (Sigma, T5648, prepared in sunflower seed oil; 20 mg ml -1 solution; 100 mg per kg intraperitoneally) for four consecutive days, followed by 2 weeks of rest. Mice received BrdU (100 mg per kg intraperitoneally) once daily for 4 d. Mice were anesthetized with Avertin (tribromoethanol; 0.018 ml (2.5%) per gram of body weight), followed by saline perfusion 24 h after the final BrdU injections. n = 6-7 mice per group.
In a separate study, young (2-month-old) heterozygous Cre + mice or Cre -littermates were injected once daily with tamoxifen (Sigma, T5648, prepared in sunflower seed oil; 20 mg ml -1 solution; 100 mg per kg intraperitoneally) for four consecutive days, followed by 16 months of aging. Mice received BrdU (100 mg per kg intraperitoneally) once daily for 5 d at 18 months of age. Mice were anesthetized with Avertin (tribromoethanol; 0.018 ml (2.5%) per gram of body weight), followed by saline perfusion 24 h after the final BrdU injections. n = 7-8 mice per group.
Conditional Vcam1-knockout mice: acute paradigm. Young (4-month-old) heterozygous Cre + mice and littermate controls lacking a copy of Cre ERT2 (Cre -) were injected intraperitoneally once daily with tamoxifen (100 mg per kg), prepared in sunflower seed oil (20 mg ml -1 solution), for four consecutive days. After a 3-d resting period, mice were treated acutely over 4 d with plasma from young (3-month-old C57BL/6J pooled male plasma, 8-10 mice pooled per sample) or aged (18-month-old C57BL/6J pooled mouse plasma, 8-10 mice pooled per sample) mice (150 µl retro-orbitally), with two injections per day separated by 10-12 h. During both the morning and evening injections on day 3 and the morning injection on day 4, mice were pulsed with BrdU (100 mg per kg intraperitoneally) to label proliferating cells. Mice received a seventh plasma injection along with a third BrdU injection on day 4 followed by perfusion 3 h after the last injection. One mouse per group received a single retro-orbital injection of 100 µg of fluorescently labeled (DyLight 488, Thermo Scientific, 53025) InVivoMAb anti-mouse-CD106 antibody (VCAM1, clone M/K-2.7, BioXcell, BE0027) and fluorescently labeled (DyLight 550, Thermo Scientific, 84530) rat anti-mouse-MECA-99 antibody (a gift of the Butcher laboratory) 3 h before perfusion.
Conditional Vcam1-knockout ice: long-term paradigm. Young (4-month-old) heterozygous Cre + mice or Cre -littermates were injected with tamoxifen (100 mg per kg intraperitoneally) for four consecutive days, followed by 12 d of rest. Plasma pooled from young or aged mice (YMP and AMP) (150 µl, retro-orbitally) was injected once every 3 d for seven total injections. Mice received BrdU (100 mg per kg intraperitoneally) for five consecutive days beginning on the fifteenth day after the start of plasma treatment. Mice were perfused 24 h after the last BrdU and plasma injections. n = 8 mice per group for four groups. One mouse per group received retro-orbital injections of 100 µg of fluorescently labeled (DyLight 488, Thermo Scientific, 53025) rat anti-mouse-VCAM1 antibody (clone M/K-2.7, BioXcell, BE0027) and fluorescently labeled (DyLight 550, Thermo Scientific, 84530) rat anti-mouse-MECA-99 antibody (a gift of the Butcher laboratory) 3 h before perfusion. Mice were anesthetized with Avertin followed by saline perfusion 16 h after the final BrdU injections.
Blood-brain barrier permeability. Aged (17-month-old) Cre + mice or Cre -littermates were injected once daily with tamoxifen (Sigma, T5648, prepared in sunflower seed oil; 20 mg ml -1 solution; 100 mg per kg intraperitoneally) for four consecutive days, followed by 2 months of rest. Mice were used to assess BBB permeability and to phenotype brain-resident leukocytes.
For a control, aged C57BL/6 mice underwent mild TBI in the cortical region, which has been shown to induce neuroinflammation and damage to the BBB, as previously described 75 . Young (5-month-old) Cre -mice (n = 4), aged Cre -and Cre + (19-month-old) mice (administered tamoxifen 2 months previously) (n = 5 mice per group) and control aged (17-month-old) mice that underwent TBI (n = 2) were injected (retroorbitally) with 200 µl of 25 mg ml -1 Texas Red-labeled 70-kDa dextran (Thermo Fisher, D1830) to probe endogenous BBB breakdown 76 . Injections were staggered to ensure PBS perfusion of each mouse 3 h after injection for optimal brain uptake 77 . Mice were anesthetized by Avertin and slowly perfused with 40 ml of cold PBS before an additional 10 ml of 5 mg ml -1 FITC-labeled 2-MDa dextran (SigmaAldrich, FD2000S) to probe large BBB breaks. The right hemisphere was fixed in 4% paraformaldehyde for immunostaining and the left hemisphere was frozen at −80 °C for tissue homogenate analysis until further processing.
The left hemisphere was thawed and suspended in 300 µl of a custom lysis buffer (200 mM Tris, 4% CHAPS, 1 M NaCl, 8 M urea, pH 8.0) . Tissues were then homogenized with a Branson Digital Sonifier sonicator set to 20% amplitude for 3 s and allowed to rest for 30 s on ice; sonication was repeated three times. Samples were centrifuged at 14,000g for 20 min at 4 °C, and supernatant was extracted for analysis. Fluorescence for FITC and Texas Red was measured with a Thermo Fisher Varioskan Flash microplate reader. Fluorescent signal was standardized to the quantity of protein per sample determined by Pierce BCA Protein Assay (Thermo Fisher, 23227).
The right hemisphere was fixed in 4% paraformaldehyde for 72 h, submerged in 30% sucrose cryoprotectant and sectioned at 40 µm with a Leica SM 2010R microtome. Hippocampal images were captured with a Zeiss LSM880 confocal microscope z stacked with nine slices at 2-µm intervals; mean fluorescence intensity was measured with ImageJ (1.51q build).
Flow cytometry analysis of brain-resident immune cells. Mice analyzed were as follows: young (3-month-old) C57BL/6J mice (n = 5), aged Cre -(n = 9) and Cre + (n = 4) 19-month-old mice administered tamoxifen at 17 months as described above in the section on BBB permeability, and aged Cre + (22-month-old) mice administered tamoxifen at 2 months of age as described in the section on basal NPC activity (n = 4).
Gates were based on positive-control LPS-stimulated Cre -aged mice injected with fluorescently labeled anti-VCAM1-DL488 monoclonal antibody or IgG-DL488 control antibody 2 h before perfusion and analysis by flow cytometry. An aged (19-month-old) Cre + littermate administered tamoxifen at 17 months as described above in the section on BBB permeability was also injected with fluorescently labeled anti-VCAM1-DL488 monoclonal antibody to confirm successful deletion of Vcam1 in the hippocampus and cortex.
Mice analyzed were anesthetized by Avertin and perfused with 20 ml of cold medium A (500 ml of HBSS, 7.5 ml of 1 M HEPES, 5.56 ml of 45% glucose, sterile filtered) for mechanical dissociation of the cortex and hippocampus. Tissue was collected and chopped in 2 ml of cold medium A with 80 µl of DNase I and then homogenized with a glass douncer. Homogenate was passed through a 100-µm cell strainer, washed three times with medium A to remove clumps and centrifuged at 340g for 7 min at 4 °C. The supernatant was removed and the pellet was resuspended in 12 ml of 25% Percoll Plus diluted in medium A (GE Healthcare, 17-5445-01) and then centrifuged at 950g for 20 min. The supernatant was discarded and the remaining cell pellet was washed with 5 ml of medium A and centrifuged at 340g for 7 min at 4 °C to remove myelin.
The myelin-free cell samples were then resuspended in 1 ml of FACS buffer (PBS + 1% BSA with 2 mM EDTA), transferred to new 2-ml Eppendorf tubes and centrifuged at 300g for 5 min at 4 °C. Cells were resuspended in 300 µl of Fc blocking solution (1:100 CD16/CD32; BD, 553141) and allowed to incubate on a shaker for 5 min at room temperature. After blocking, primary antibodies against Ly6C, Ly6G, TMEM119, α 4 β 1 (VLA-4), CD45, CD11c, IA/IE, CD14, CD19, CD3, CD11b and CD206 were added to the samples and allowed to incubate for 15 min. FACS buffer was added to the samples to a final volume of 1 ml and samples were centrifuged at 400g for 5 min. Samples were then incubated in 300 µl of solution with secondary antibodies, streptavidin and Alexa Fluor dye for 15 min. FACS buffer was added to the samples to a final volume of 1 ml and samples were centrifuged at 400g for 5 min. Samples were washed with 1 ml of FACS buffer and stained with a viability dye (Bioscience Fixable Viability Dye eFluor 506, Thermo Fisher, 65-0866-14) . Samples were then washed in 1 ml of FACS buffer, centrifuged and resuspended in 500 µl of FACS buffer and were filtered through a 40-µm cell strainer cap into round-bottom tubes for flow cytometry analysis (Falcon, 32235) .
Antibodies for immune cell profiling with flow cytometry. Full information on the antibodies used is available in Supplementary Table 6 .
Behavioral testing. Anti-VCAM1 dosing paradigm. Aged (17-month-old) or adult (5-month-old) C57BL/6J male mice were injected with anti-VCAM1 monoclonal antibody (BioXcell, BE0027) or IgG isotype control (BioXcell, BE0088), 9 mg per kg intraperitoneally every 3 d for a total of eight injections over a 3-week period. Behavioral testing began at the start of week 4, and antibody injections continued every 3 d throughout the testing period.
Thirteen-month-old NSG mice (n = 11 mice per group) were injected with anti-VCAM1 monoclonal antibody or IgG1 isotype control (9 mg per kg intraperitoneally) every 3 d for nine injections over 4 weeks. Behavioral experiments were performed between the seventh and ninth injections with antibodies during the last week.
Twenty-three-month-old C57BL/6 males ('WT') were treated with anti-VCAM1 antibody (n = 13), IgG (n = 12) or PBS (n = 7). They each received ten intraperitoneal injections (9 mg per kg) of antibody every 3 d for 4 weeks. Behavioral experiments were performed between the eighth and tenth injections with antibodies.
Behavioral testing was performed in a controlled environment as previously described 78, 79 . Tests were performed in groups of four mice at a time with even lighting conditions (30 ± 5 lumens). All trials were recorded using a ceilingmounted camera and Topscan version 2.00 software. All equipment was thoroughly cleaned with 70% ethanol between trials.
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Novel object recognition . The novel object recognition test was performed in a large acrylic cube measuring 45 cm (17.75 in) tall by 44.5 cm (17.5 in) wide with a light cerulean bottom. On day 1 of testing, the mice were allowed to habituate to the testing environment for 5 min. Two objects, a black cat/tabby cat or gray cat/ orange dog (silicon toys measuring 5.1 cm (2 in) tall by 3.2 cm (1.25 in) wide), were placed along one wall of the cubic field 5.1 cm (2 in) away from the corners. The mice were placed inside the cubic field facing away from the objects and allowed 15 min to explore and interact with the objects. On day 2 of testing, one of the two objects in each field, the tabby cat and orange dog, was replaced by a novel object, an orange tiger and yellow lion, respectively, while the second object (black cat and gray cat) was kept constant from day 1. The mice were placed inside the field facing away from the objects and allowed 15 min to explore and interact with the objects. Object interaction was defined as close investigation within 1 cm of the object. Novel object interaction percentage was calculated with the formula (time interaction with novel object × 100)/(time interaction with sample object + time interaction with novel object) from day 2. Sample object interaction percentage was calculated by using the formula (time interaction with sample object × 100)/ (time interaction with sample object + time interaction with novel object) from day 2. Interaction times were manually scored by the observer. Corresponding data are shown in Extended Data Fig. 9 .
Novel object recognition was also performed as previously described, with minor modifications 80 . Briefly, mice were first habituated to the open-field arena (40 cm × 40 cm × 35 cm), which contained wall-mounted visual cues, for a period of 5 min. Mice were given one 5-min trial during which they explored two identical objects in fixed positions. Mice were randomly assigned to identical starting objects of either 25-ml cell culture flasks filled with sand or Lego towers (3 cm × 3 cm × 7.5 cm). Subsequently, mice explored the same arena for 5 min but with one object replaced with the novel, distinct object. Interactions with objects (sniffing or exploring within 2 cm of the object; excluding time spent sitting on top of the object) were manually timed in a blinded fashion to assess the percentage of time spent exploring each object: (single object interaction time)/(total interaction time with both objects) × 100. Corresponding data are shown in Fig. 6 .
Fear conditioning. The fear conditioning test was performed as previously described 11 . In brief, a prefabricated electric shock cage was set at 0.70 mAh for NSG mice and at 0.45 mAh for B6 mice. A 6-min training session was conducted on day 1. Tone and light cues were given three times for 20 s each at 180 s, 240 s and 300 s. Each tone and light cue ended in a 2-s foot shock. On day 2 of the cued recall trial, a white block of acrylic was inserted into the shock cage to alter the shape of the cage; these blocks were cleaned with 4% acetic acid between trials to eliminate odor cues. Mice were tested for a cued recall response for 6 min with tone and light cues given three times for 20 s each at 180 s, 240 s and 300 s. In the afternoon of day 2, a contextual recall trial was performed for 5 min where no tone or light cues were given. Trials were recorded with FreezeScanLite software and the percentage freezing was determined on the basis of motion detection by the software.
Barnes maze. A modified Barnes maze test was performed similarly to the test previously described 11 and tailored minimally to accommodate the mild deficiencies of aged mice. Briefly, a large circular maze containing 16 holes on the outer edge was centered over a pedestal and elevated approximately 120 cm above the floor. The escape hole consisted of a PVC elbow joint connector that was similar in texture to the maze, while the other holes were left open to the floor. Distinct visual cues were placed at four equally spaced points around the maze. An overhead light, two additional standing lights and a fan blowing on the maze provided motivation to find the escape hole. The escape hole position was fixed for all days of the task. Mice performed four trials per day for 5 d as follows. For each trial conducted on the same day, the starting location for the mouse was altered relative to the escape hole position. If mice failed to identify the escape hole within 90 s, they were gently guided by light tapping/directing toward the escape hole and given a score of 90 s. Between each trial, both the maze and escape hole were thoroughly cleaned with 10% ethanol to remove any scent cues that might affect performance in subsequent trials.
Tissue processing. Mice were anesthetized with Avertin (2,2,2-tribromoethanol: T48402, Sigma-Aldrich; 2-methyl-2-butanol: 240486, Sigma-Aldrich) (0.018 ml (2.5%) per gram of body weight) before they were killed. Then, 0.5 ml of blood was collected from the right ventricle of the heart in 250 mM EDTA and kept on ice until further processing. Mice were perfused with 20 ml of PBS. Blood was centrifuged at 1,000g for 10 min at 4 °C; plasma was rapidly frozen with dry ice and stored at −80 °C until further processing. Brains were collected and divided sagittally. One hemisphere was used to dissect the hippocampus and cortex, which was snap frozen and stored at −80 °C. The second hemisphere was fixed in phosphate-buffered 4% paraformaldehyde for 72 h at 4 °C before transfer to 30% sucrose in PBS at 4 °C for 48 h. Brains were frozen at −30 °C and cryosectioned coronally at 40 µm with a microtome (Leica, SM2010R). Brain sections were stored in cryoprotectant (40% PBS, 30% glycerol, 30% ethylene glycol) and kept at −20 °C until staining.
Immunostaining. Staining without BrdU or EdU. Brain sections were washed three times for 10 min in TBST and then blocked in TBS++ (TBS + 3% donkey serum (130787, Jackson ImmunoResearch) + 0.25% Triton X-100 (T8787, SigmaAldrich)) for 1.5 h, followed by incubation for 72 h on a rocking platform at 4 ˚C in primary antibodies (see antibodies listed below). For secondary staining, brain sections were washed three times for 10 min in TBST, followed by incubation for 1.5 h in secondary antibody mix. Following incubation with secondary antibody, there were four 10-min washes in TBST; the second wash contained Hoechst (1:2,000) with TBST. Brain sections were mounted on Superfrost microscope slides Fisher Scientific) with Flouromount Aqueous Mounting Medium (Sigma-Aldrich, F4680). Slides were stored at 4 ˚C.
EdU staining. Brain sections were washed three times for 10 min in TBST and then blocked in TBS++ (TBS + 3% donkey serum + 0.25% Triton X-100) for 1.5 h, followed by incubation for 72 h on a rocking platform at 4 °C in primary antibodies (see antibodies listed below). For secondary staining, brain sections were washed three times for 10 min in TBST, followed by incubation for 1.5 h in secondary antibody mix. After secondary staining, sections were washed three times in TBST followed by fixation for 50 min with 4% paraformaldehyde and three 10-min washes in TBST. EdU staining was performed following the instructions in the manual for the imaging kit (C10637, Life Technologies). Four 10-min washes, of which the third wash contained Hoechst (1:2,000), were performed with TBST before mounting with Flouromount and slides were stored at 4 °C.
BrdU staining. Brain sections were washed three times for 10 min in TBST and then transferred to 95 °C for 10 min in 10 mM sodium citrate (pH 6), followed by three 10-min washes in TBST. Sections were incubated in 3 M HCl for 30 min at 37 °C and then washed three times for 10 min in TBST. Sections were blocked for 1.5 h in TBS++ and then transferred to primary antibody mix for incubation for 72 h on a rocking platform at 4 °C. Secondary staining started with three washes for 10 min in TBST, followed by incubation with secondary antibody mix for 1.5 h (all antibodies listed below). After three 10-min washes in TBST, sections were mounted with Flouromount. Slides were stored at 4 °C.
ELISA.
Mouse plasma samples were used to measure sVCAM1 with the VCAM1 ELISA kit (Raybiotech, ELM-VCAM-1) according to the instructions in the manual. sVCAM1 was measured in human plasma samples with the Human sVCAM-1/CD106 Quantikine ELISA kit (R&D Systems, DVC00), following the instructions in the manual. Optical density was measured at 450 nm and 540 nm on a Varioskan Flash Multimode Reader (5250040, Thermo Scientific). were captured on a Zeiss confocal microscope for each brain sample, and cells within the dentate GCL were counted. NPC activity was quantified by counting co-labeled precursor cell populations in the neurogenic granular layer and hilus in six serial 40-µm sections throughout the hippocampal DG. Counts were made while blinded to the different groups. Cell numbers were normalized to the volume of the GCL of the DG. Unless otherwise noted, all representative confocal images were captured on a Zeiss confocal microscope and represent a z stack of ten images taken on confocal planes 2 µm apart. Images of cells cultured in vitro (Extended Data Fig. 2 ) were captured on a single plane.
3D rendering of high-magnification immunofluorescence.
Images (×63 magnification; z stacked) were captured with an LSM700 system set to take 51 slices with an interval of 0.4 µm. 3D modeling through Imaris8 software was done on the z-stacked images for high-contour modeling of antibody markers. Surface masks with smoothing set to 0.2 µm were used to form the base 3D model. Surface area and voxel thresholds were used to remove artifacts from high-magnification image acquisition.
For quantifications of the percentage area in immunofluorescence images, ImageJ was used to determine the integrated pixel intensity of thresholded images comprising 5-6 serial 40-µm sections spanning the hippocampal DG per mouse immunostained for various vasculature and microglial cell markers.
Vasculature. Confocal z stacks of six coronal brain sections spanning the hippocampus (40 mm thick, 200 mm apart) were captured on a Zeiss confocal microscope for each brain sample. VCAM1 and lectin signals were thresholded and analyzed with '% Area' of the ' Analyze Particles' function in ImageJ 1.50i (https:// imagej.nih.gov/ij/). Autofluorescence background picked up by the thresholds was removed by using the Size Exclusion feature of the ' Analyze Particles' function. Colocalized VCAM1 + and lectin + signal was calculated using the Colocalization plug-in developed by Pierre Bourdoncle of the Institut Jacques Monod (http://rsb. info.nih.gov/ij/plugins/colocalization.html).
Microglial activation. Confocal z stacks of six coronal brain sections spanning the hippocampus (40 mm thick, 200 mm apart) were captured on a Zeiss confocal microscope for each brain sample. The microglial markers IBA1 and CD68 were analyzed through '% Area' and manual cell counts; IBA1 and CD68 signals were threshold and analyzed with '% Area' of the ' Analyze Particles' function of ImageJ 1.50i. Colocalized IBA1 and CD68 signal was calculated by using the Colocalization plug-in (http://rsb.info.nih.gov/ij/plugins/colocalization.html). To count the numbers of IBA1 + and IBA1 Statistical tests. Data were analyzed with an unpaired Student's t test and one-or two-way ANOVA with Tukey's multiple-comparisons test or Sidak's multiplecomparisons test, respectively. Proteomics data were analyzed by Spearman's correlation coefficient. Bulk RNA-seq data were analyzed by using the Cuffdiff v2.2.1 statistical package. scRNA-seq data were analyzed by applying the Mann-Whitney U test to the BEC clusters obtained from unsupervised clustering. P values were adjusted via FDR or Bonferroni correction. P values equal to or lower than 0.05 were considered statistically significant. Significance was assessed on the basis of P values and heteroscedastic variance between groups that were statistically compared. For the violin plots, the data corresponding to the minima, maxima, center and percentile values in Fig. 1 
Data availability
RNA-seq gene lists with statistics ( Figs. 1 and 2 , and Extended Data Figs. 1 and 2 ), full blots (Extended Data Fig. 6 ) and individual data points graphed for Extended Data Fig. 9n are available as source data files and as Supplementary Tables 1-6 accompanying this article. Requests for datasets obtained from human research will be subject to additional review steps by the IRB that granted the permit for particular research. Bulk and scRNA-seq datasets that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) with the series accession number GSE127758 (embedded accession codes GSM3638211 to GSM3638222) and GSE127963. Please contact the corresponding author for additional information. 
Cd11b
-CD45 -cells were defined as the BEC population. c, FPKM values of CNS cell-typespecific markers. n = 6 young and 6 aged biologically independent samples. Data are shown as the mean ± s.e.m. d, FPKM values of leukocyte binding adhesion molecules, including Vcam1. n = 6 young and 6 aged biologically independent samples. Bars show the mean; error bars are derived from s.e.m. Specific q values shown were derived from the Cuffdiff statistical package (*q = 0.0015). See the Methods for details; source data are available online. e, FPKM values of tight junction genes. n = 6 young and 6 aged biologically independent samples. Data are shown as the mean ± s.e.m. q = 0.16, *q = 0.0013, **q = 0.0015, Cuffdiff statistical package. See the Methods for details; source data are available online. f, FPKM values of transcripts in young and aged mouse CD31
+ BECs corresponding to human plasma proteins that change with age (see Supplementary Table 2 for a list of human plasma proteins expressed in mouse BECs). n = 6 young and 6 aged biologically independent samples. Data are shown as the mean ± s.e.m. *q = 0.0015, **q = 0.021, Cuffdiff statistical package. See the Methods for details; source data are available online. g, C57BL/6 mice were injected with anti-VCAM1-DL488 or IgG-DL488 isotype control (r.o.) 2 h before perfusion to label BECs in vivo followed by brain dissociation, staining and FACS. h, Flow gating and histogram plots of pooled (n = 4 mice per age group) young or aged hippocampi isolated from healthy mice injected with anti-VCAM1-DL488 or IgG-DL488 isotype control as depicted in g. i, Quantification of CD31 + VCAM1 + cells isolated from healthy cortices (n = 4 mice per age group, individually measured) (left) and four technical replicates of hippocampi that were pooled from four mice per age group (right). Data are shown as the mean ± s.e.m. *P = 0.0015, two-tailed Student's t test. j, sVCAM1 ELISA in plasma from young isochronic or heterochronic parabionts following 5 weeks of parabiosis. n = 11 mice per group pooled from two independent experiments. **P = 0.0031, two-tailed Student's t test. Data are shown as the mean ± s.e.m. k, Confocal images in the DG of VCAM1, lectin and AQP4 of young isochronic or heterochronic parabionts 5 weeks after surgery. Quantification is shown in Fig. 1j . Hoechst labels cell nuclei. Scale bar, 100 µm. n = 8 mice in the young isochronic group and 13 mice in the young heterochronic group from two independent experiments; representative images are shown. l, Box plot of expression levels of classical pan-endothelial and BBB-specific transcripts (n = 272 BECs in total). Minima, maxima, medians and percentiles are listed in Supplementary 
VCAM1
+ cells. n = 2 pooled samples per condition. e, CD31 and VCAM1 quantification (left) and histogram (right) of Bend.3 cells stimulated overnight with recombinant mouse TNF-α, IL-1β or IL-6 followed by flow cytometry to measure VCAM1. n = 3 biologically independent samples per condition. ****P < 0.0001, one-way ANOVA with Tukey's post hoc test for group comparisons. Data are shown as the mean ± s.e.m; experiment repeated four times independently with similar results. f, Primary BECs and Bend.3 cells cultured in 10% plasma from young or aged mice (YMP, 3 months old; AMP, 18 months old) or young or aged humans (<25 years or >65 years, YHP/ AHP) for 16 h and then stained for VCAM1. Representative images are shown. Scale bar, 100 µm. Each plasma treatment experiment in primary BECs or Bend.3 cells with mouse or human plasma was repeated at least three times independently with similar results. g, Quantification of the percentage of area with VCAM1 staining. Primary BECs treated with plasma from young or aged mice: n = 7 YMP and 9 AMP biologically independent replicates pooled from two experiments. *P = 0.0343. Bend.3 cells with YMP or AMP: n = 4 biologically independent replicates per group derived from different cell flasks. ***P = 0.0003. Bend.3 cells with YHP or AHP: n = 6 biologically independent replicates derived from different cell flasks per group. ****P < 0.0001. P values were determined by two-tailed Student's t test. Data are shown as the mean ± s.e.m. h, Bend.3 cells cultured in 10% plasma from young or aged mice for 16 h followed by flow cytometry for CD31 and VCAM1. n = 5 biologically independent replicates per group. A graph of CD31 and VCAM1 quantification is shown with a histogram of Bend.3 cells. **P = 0.0082, two-tailed Student's t test. Data are shown as the mean ± s.e.m. i, Quantification of the percentage of CD31 + Bend.3 cells treated with plasma from young or aged mice and co-stained for CD31 and ICAM1, E-selectin or P-selectin. n = 5 biologically independent replicates per group for ICAM1; n = 6 biologically independent replicates per group for E-selectin and P-selectin. Data are shown as the mean ± s.e.m. Histogram plots are shown to the right of quantification. Not significant; P = 0.2355 (ICAM1), P = 0.1959 (E-selectin), P = 0.0825 (P-selectin), two-tailed Student's t test. j, Representative images of ICAM1, MECA-99, lectin and Hoechst (to label cell nuclei) of young (3-month-old) mice that received seven retro-orbital injections of pooled plasma from young (3-month-old) or aged (18-month-old) mice over 4 d as described in the schematic in Fig. 3a . n = 10 mice treated with YMP and 11 mice treated with AMP. Scale bar, 100 µm. k, Quantification on the right using n = 4 mice per group. Data are shown as the mean ± s.e.m. Not significant; P = 0.5222, two-tailed Student's t test. l,m, Quantification in the DG of total BrdU + SOX2 + NPCs in young (3-month-old) mice injected retro-orbitally daily over 5 d (2 µg per injection) with TNF-α (n = 4 mice per group) or with three LPS injections (0.5 mg per kg intraperitoneally) at 28 h, 22 h and 2 h before perfusion (n = 8 mice per group). In each experiment, mice were pulsed with BrdU every 8 h for three injections before perfusion. *P = 0.0194 (TNF-α), *P = 0.0122 (LPS), two-tailed Student's t test. Data are shown as the mean ± s.e.m.
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Extended Data Fig. 6 | Circulating sVCAM1 does not contribute to inhibitory effects of administration of plasma from aged individuals while anti-VCAM1 antibody prevents the inhibitory effects of plasma from aged humans. a, Experimental design. n = 7 mice per group. 
SOX2
+ NPCs in the DG of immunostained sections. n = 7 mice per group. Data are shown as the mean ± s.e.m. *P = 0.0237, **P = 0.0123, ***P = 0.0320, ****P = 0.0094, one-way ANOVA with Tukey's multiple-comparisons post hoc test. h,i, Quantification (h) and representative confocal images (i) of the DG for DCX and Hoechst (to label cell nuclei). Scale bar, 100 µm. n = 5 mice per group analyzed. Data are shown as the mean ± s.e.m. **P = 0.0017, *P = 0.0385, one-way ANOVA with Tukey's multiple-comparisons post hoc test. j, Quantification of the IBA1 and CD68 staining from confocal images in the DG. n = 7 mice per group. *P = 0.0156, **P = 0.0242, ***P = 0.0034, ****P = 0.0237, P = 0.0546 (PBS as compared to anti-VCAM1 activated microglia counts), one-way ANOVA with Tukey's multiple-comparisons post hoc test. Data are shown as the mean ± s.e.m. k, Experiment schematic. n = 9 PBS-treated, 8 AHP + IgG-treated and 8 AHP + anti-VCAM1 monoclonal-antibody-treated mice. l, Quantification in the DG of VCAM1 in lectin + blood vessels from immunostained confocal images. n = 9 PBS-treated, 8 AHP + IgG-treated and 7 AHP + anti-VCAM1 monoclonal-antibody-treated mice analyzed. Data are shown as the mean ± s.e.m. **P = 0.006, one-way ANOVA with Tukey's multiple-comparisons post hoc test. m, Quantification in the DG of CD68 in IBA1 + stained microglia from immunostained confocal images. n = 9 PBS-treated, 8 AHP + IgG-treated and 8 AHP + anti-VCAM1 monoclonal-antibody-treated mice. Data are shown as the mean ± s.e.m. ***P = 0.0006, **P = 0.0067, one-way ANOVA with Tukey's multiple-comparisons post hoc test. n,o, Quantification of BrdU + SOX2 + progenitor cells (n) and DCX + immature neurons (o) from confocal images. n = 9 PBS-treated, 8 AHP + IgG-treated and 8 AHP + anti-VCAM1 monoclonal-antibody-treated mice. Data are shown as the mean ± s.e.m. *P = 0.018, **P = 0.0386, ***P = 0.0344, ****P = 0.0167, one-way ANOVA with Tukey's multiple-comparisons post hoc test. p, Quantification of the total numbers of EdU + surviving cells in the DG of immunostained sections. n = 9 PBS-treated, 8 AHP + IgG-treated and 8 AHP + anti-VCAM1 monoclonal-antibody-treated mice. Data are shown as the mean ± s.e.m. ***P = 0.0009, ****P = 0.0002, one-way ANOVA with Tukey's multiple-comparisons post hoc test.
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Extended Data Fig. 7 | BBB integrity is not compromised with aging or conditional deletion (19-month-old) mice, which are Cre + mice that were treated with tamoxifen for 4 d, 2 months before they were killed, and that were infused with dextran before being killed as described in a. Data are shown as the mean ± s.e.m. c,d, Quantification of mean fluorescence intensity from confocal images of tissue sections from mice injected as in a and b. Cre -and Cre + mice were used as described in a. n = 4 young Cre -mice, 5 aged Cre -mice, 5 aged Vcam1-ST Cre + mice that were treated with tamoxifen and that were infused with dextran as described in a and b, and 1 young and 1 aged Cre -control mice not infused with dextran. Data are shown as the mean ± s.e.m. P = 0.895 (young versus aged), 0.9097 (aged versus aged Vcam1-ST), one-way ANOVA with Tukey's multiple-comparisons post hoc test. e, Schematic of flow cytometry analysis of various immune cell populations from mouse cortex and hippocampus. f, Flow cytometry gating strategy for individual hippocampal immune cell populations labeled for various immune cell markers, including α 4 β 1 integrins (VLA-4). n-1 was used to gate for VLA-4 + cell populations. 
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+ hippocampal and cortex cells isolated from one LPS-stimulated aged (19-month-old) Cre + (Vcam1 deletion short term) mouse and one Cre -mouse injected with anti-VCAM1-DL488 (r.o.) 2 h before killing to confirm VCAM1 levels on BECs were reduced. One additional Cre -mouse was treated with LPS and injected with IgG-DL488 isotype control before killing to serve as a control for VCAM1 gating. c-j, Quantification of various cell populations present in young Cre -(n = 5), aged Cre -(n = 9), aged Vcam1-LT (n = 4) and aged Vcam1-ST (n = 4) mice per group. Data are shown as the mean ± s.e.m. *P = 0.0413, **P = 0.0245, ***P = 0.0429, ****P = 0.0023, one-way ANOVA with Tukey's multiple-comparisons post hoc test.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Behavior testing was performed in a controlled environment as described in methods.Tests were performed in groups of 4 mice at a time with even lighting conditions (30 ± 5 lumens). All trials were recorded using a ceiling mounted camera and Topscan Version 2.00 Software. Data was analyzed using Prism.
Data analysis
Image analysis: Prism (6.0h and 8.0.1), ImageJ (1.51q Build) 3D Image Rendering: Imaris8 (v.8.0.2) Flow Cytometry Analysis: FlowJo (v.10.0) and FACSDiva (v.8.0.1) Bulk RNAseq Analysis: FastQC v0.11.2 was used to provide quality control checks on the raw RNAseq sequence data. STAR v2.4.2a was used to align the RNAseq reads to the mouse reference genome (mm9). Cuffdiff v2.2.1 statistical package was used to perform differential expression analysis for RNAseq based on gene and transcript abundance measurements in terms of Fragments Per Kilobase of transcript per Million mapped reads (FPKM), as previously described61. R v3.2.2 statistical package and CummeRbund v2.12.1 R/ Bioconductor package were used for visualization of the various output files of the Cuffdiff differential expression analysis including visualization of the changes in gene transcripts with age. FPKM values for genes and transcripts were tabulated and Cluster v3.0 was used to perform hierarchical clustering and cluster analysis. Java TreeView v1.1.6 was used to visualize the output files from hierarchical clustering in the form of heat maps displaying up-or down-differentially regulated genes in aged versus young BECs. Gene Set Enrichment Analysis (GSEA v2.2.0) tool was used to determine whether GO and Pathway gene sets showed statistically significant, concordant differences between young and aged BECs. Proteomic Analysis: R Segmented package (v3.2.2) scRNAseq: Sequences from the Nextseq were demultiplexed using bcl2fastq, and reads were aligned to the mm10 genome augmented 2 nature research | reporting summary October 2018
